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AP: Action potential 
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Background - Cardiovascular disease (CVD) and cancer remain the two most 
common causes of mortality in developed countries. It is believed that cancer 
may interact with the host organs both in the microenvironment and at a distant 
anatomic site. Gastrointestinal (GI) cancers are a group of highly aggressive 
malignancies with heavy cancer-related mortalities. More and more evidences 
suggest a correlation between cancer and arrhythmias. However, there are no 
experimental studies investigating the effects of cancer cell secretion on ion 
channel function in human cardiomyocytes. DNA methylation, which is mainly 
established and maintained by DNA methyltransferases (DNMTs) by adding 
methyl groups to DNA molecules, is one of the mechanisms of epigenetic 
regulations. Recent researches suggest that DNA methylation can respond to 
external stimuli and is related to the functional status of cells in cardiovascular 
disease. Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-
CMs) have been demonstrated to recapitulate the physiological and 
pathological features of human cardiomyocytes and therefore are useful for 
studies on human cardiac diseases.   
Purposes - The study was designed to assess the possible effects of 
gastrointestinal cancer cell secretion on cardiac ion channel functions and 
explore the underlying epigenetic mechanism by using hiPSC-CMs. 
Methods - The hiPSC-CMs generated from human skin fibroblasts of a healthy 
donor were treated by GI cancer cell (AGS or SW480 cells, cultured for 8 days) 
medium in different concentrations (the cancer cell secretion groups) or the 
same medium without cancer cell culture (medium control) for 48 hours, and 
hiPSC-CMs without any treatment were taken as control group. Then qPCR, 
patch-clamp, western blotting, immunostaining, dot blotting, bisulfite sequence 
and overexpression of the ten-eleven translocation (TET) family enzymes were 




Results - Patch clamp recordings of action potentials (AP) exhibited that the 
maximum depolarization velocity (Vmax) and the action potential amplitude (APA) 
were reduced in cancer cell secretion groups compared with control. The action 
potential duration at 10% repolarization (APD10) prolonged in cancer cell 
secretion groups. In ion channel current measurements, peak Na+ current (INa) 
was significantly reduced in cancer cell secretion groups, in agreement with the 
Vmax and APA reduction. The transient outward current (Ito) was decreased in 
presence of cancer cell secretion compared with control group, consistent with 
the APD10 prolongation. Both the late Na+ and the slowly activating delayed 
rectifier K+ current (IKs) were significantly increased. qPCR results showed that 
the expression of SCN5A (Na+ channel, Nav1.5) and KCND3 (Ito, Kv4.3) were 
decreased, while SCN10A (Na+ channel, Nav1.8) and KCNQ1 (IKs, Kv7.1) were 
increased by cancer cell secretion. Furthermore, the changes of protein 
expression level of ion channels determined by western blotting and 
immunofluorescence, respectively, were in consistent with the results of qPCR 
and current measurements. The whole genome DNA methylation level 
detected by 5-mC antibody was increased in cancer cell secretion groups, 
along with increased protein levels of DNMT3A and DNMT3B, but no 
differences of 5-hmC level were observed. After overexpression of TET1 
enzyme that is responsible for DNA demethylation, DNA methylation level of 5-
mC of the cancer cell secretion groups was decreased and both the current and 
protein expression level of Ito and IKs channels were rescued. 
Conclusions - Gastrointestinal cancer cell secretion can induce ion channel 
dysfunctions and subsequently abnormal action potentials, which may 
contribute to occurrence of arrhythmias in cancer patients. The ion channel 
dysfunctions might result from DNA methylation of ion channel genes. 
Key words - Gastrointestinal cancer cell secretion; hiPSC; cardiomyocyte; 





Cardiovascular disease (CVD) and cancer are the two most common causes 
of mortality worldwide.1, 2 Data from World Health Organization in 2018 show 
that worldwide about 18 millions of people die from CVD annually,3 while about 
18 million patients suffer from and about 10 million die of cancer.4 Due to the 
success of basic and therapeutic researches, cancer treatments have become 
more effective. Also improved diagnostic and therapeutic modalities achieve 
remarkable progress in improving the survival rates of cancer patients. It has 
been reported by the American Cancer Society that there were more than 15.5 
million cancer survivors in the USA in 2016, and this number was projected to 
reach more than 20 million by year 2024.5 However, the improvement of 
survival rate in cancer patients may be limited by adverse effects associated 
with anti-cancer treatment. A survey conducted by the US National Health and 
Nutrition Examination showed that 51% of 1807 cancer survivors died of cancer 
and 33% died of heart disease in 7 years follow-up,6 including the development 
of newly diagnosed cardiovascular problems, or the exacerbation of previously 
identified cardiovascular disease.1 Among the anti-cancer therapy related 
adverse effects, cardiotoxicity is the second most common cause of morbidity 
and mortality.7 The cardiovascular toxicity of cancer treatment, which manifests 
as cardiac dysfunctions, remains a major obstacle for cancer survival. It may 
compromise the effectiveness of the anticancer therapy and can negatively 
affect the survival or life quality of oncological patients.7, 8 The rise in the 
incidence of CVD among patients affected by cancers has drawn attention. 
Even worse, in some cancer patients, cardiovascular deaths are more common 
than cancer deaths.9 The risk of atrial fibrillation, which is one of the most 
common arrhythmias in cancer patients, may be higher than that in patients 
without cancer.10, 11 The newly-onset of atrial fibrillation in cancer patients may 
reflect a more advanced cancer stage and herald a poorer oncological 




therapy, cancer could increase the risk of venous thromboembolism (VTE) 4 to 
7 times and the risk of bleeding 2 times.12, 13 The cardiovascular problems are 
involved in primary or secondary malignancies, as well as the result of 
cardiotoxicity in cancer treatments (including chemotherapy, radiation, and 
adjuvant therapies) with adverse effects on heart function and structure.9 The 
potential cardiovascular toxicity of anti-cancer agents includes QT prolongation, 
arrhythmias, myocardial ischemia, stroke, hypertension, thromboembolism, left 
ventricular dysfunction, and heart failure.14 In order to alleviate the cardiotoxicity 
of cancer treatment, methods have been applied, such as the introduction of 
highly sensitive diagnostics, coadministration of dexrazoxane, and application 
of new forms and less toxic chemotherapy analogs. However, there is no 
recommendation for cardiovascular drugs used to protect the heart function for 
cancer patients. Only the “2016 European Guidelines on cardiovascular 
disease prevention in clinical practice” announced that prophylactic treatment 
should be performed as early as possible to minimize the cardiotoxicity of 
anthracyclines in high-risk patients.15 
  Most researches focus on the cardiotoxicity of anti-cancer therapy, but 
cancer itself could affect cardiovascular system. Tumors are believed to 
influence the microenvironment to promote their proliferation, migration, 
invasion, metastasis, and also therapy resistance.16 However, evidences have 
revealed that tumor could interact with the host beyond the local tissue 
microenvironment and actively perturb host organs at distant anatomic sites.17 
It has been reported that the incidence of CVD is 10-fold higher in cancer 
survivors than that in controls, along with higher rates of congestive heart failure 
and stroke, and higher incidence of cardiovascular risk factors.18, 19 Tumors can 
cause arrhythmia in cancer patients through direct infiltration, systematic 
inflammation, metabolic derangements, impaired oxygenation, and electrolyte 
or endocrine abnormalities.20 A study demonstrated that heart rate variability 




cancer.21 Another study on acute leukemia patients found that cardiac 
autonomic functions were changed with a decrease in heart rate variability.22 In 
addition, one epidemiologic analysis from health insurance research database 
including 24,125 newly diagnosed patients with malignant disease identified 
during the study period revealed that patients with cancer had a higher risk of 
developing atrial fibrillation, with 1.8% who experienced newly onset atrial 
fibrillation after cancer diagnosis, and 2.4% who had pre-existing atrial 
fibrillation.23 Another study suggested that cancer patients with a preserved 
ejection fraction, irrespective of cancer drug therapies, had evidence of 
subclinical myocardial dysfunction, manifested by a decrease in circumferential 
and radial tension.24 These findings further demonstrate that a tumor may itself 
have a deleterious effect on myocardial function of heart. Animal study also 
reported that mice injected with lung carcinoma cells showed degenerative 
structural cardiac lesions and a significant reduction in myocardial innervation25. 
Overall, the aforementioned evidences indicate that cancer may affect the 
electrophysiology of cardiomyocytes, independent of cancer therapy. 
Gastrointestinal cancers are a group of highly aggressive malignancies with 
heavy cancer-related mortalities.16 It has been reported that patients with GI 
cancers showed lower heart rate variability.26 Atrial fibrillation is the most 
common form of cardiac arrhythmia, and it becomes an epidemic as population 
ages. Recently, the association between the incidence of atrial fibrillation and 
colorectal cancer has drawn much attention. A study found that patients with 
colorectal cancer have a 2-fold higher incidence of atrial fibrillation than patients 
with non-neoplastic diseases.27 However, there are no experimental studies 
investigating the potential role of GI cancers on cardio electrophysiology. In the 
present study, we aim to assess the possible cardiac effects induced by 
gastrointestinal cancer cell secretion and explore their electrophysiological and 




Epigenetic modification represents all genetic changes in meiosis and mitosis 
inheritance that do not involve a change in the DNA nucleotide sequence itself, 
but will affect the tight packaging of DNA and the ability to be accessed by 
transcription factors.28 It is an important and heritable mechanism of gene 
expression regulation. Epigenetic mechanisms such as histone tail modification 
and DNA methylation may contribute to differential gene regulation. Among 
epigenetic changes, DNA methylation is one of the earliest and most thoroughly 
studied mechanisms of epigenetic modifications.29, 30 Generally, DNA 
methylation is consistently high throughout the genome, with 60-80% of CpG 
methylating.31 It occurs at the cytosine residue of CG doublet sequences, which 
form clusters known as CpG islands and trend to be located at 5’ gene promoter 
regions. Methylation of CpG islands at promoters may physically impede the 
binding of transcriptional proteins to the gene, which is correlated with strong 
repressive effect of transcription.32 The DNA methylation process is primarily 
regulated by DNA methyltransferases (DNMTs) and ten-eleven translocation 
(TET) family enzymes.33 Three DNMTs (DNMT1, DNMT3a and DNMT3b) are 
required for establishment and maintenance of DNA methylation patterns. Two 
additional enzymes (DNMT2 and DNMT3L) may also have more specialized 
but related functions.34, 35 DNMT1 appears to be responsible for the 
maintenance of established patterns of DNA methylation, while DNMT3a and 
3b seem to mediate establishment of new DNA methylation patterns.36 
DNA demethylation is the removal of a methyl group from DNA. This 
mechanism is equally as important as and coupled with DNA methylation. The 
TET family of 5-methylcytosine (5-mC) hydroxylases includes TET1, TET2 and 
TET3. These proteins may promote DNA demethylation by binding to CpG rich 
regions to prevent unwanted DNA methyltransferase activity, and by converting 
5-mC to 5-hydroxymethylcytosine (5-hmC), 5-hmC to 5-formylcytosine (5-fC), 
and 5-fC to 5-carboxylcytosine (5-caC) through hydroxylase activity.37 TET1 




essential for oocyte reprogramming. DNMT3a and TET1 cooperate to regulate 
promoter epigenetic landscapes in mouse embryonic stem cells.31 Whole 
genome examination of the cardiomyocytes from embryos, newborns, adults 
and hypertrophic mice found that TET-mediated DNA methylation can regulate 
the expression of key cardiac genes such as myosin heavy chain 7 (Myh7), 
indicating that this epigenetic mechanism plays an important role in the 
development and disease of the heart.38 
DNA methylation is crucial to regulate the functioning of the genome and has 
an important impact on normal cell physiology, including development, 
differentiation and DNA protein interactions. Increasing evidence suggests that 
external stimuli, like environmental and lifestyle factors, may affect gene 
expression by disrupting DNA methylation patterns. Lifestyle factors such as 
nutrition and exercise could change epigenetics. Abnormal patterns of DNA 
methylation can induce many diseases, such as cancer, autoimmune diseases, 
inflammatory disease, and atherosclerosis. Other chronic diseases, including 
metabolic diseases like obesity, metabolic syndrome and diabetes, are also 
prone to epigenetic modifications.39 Recent researches also suggest that DNA 
methylation can respond to external stimuli and is related to the functional 
status of cells in cardiovascular disease. Some results imply that reduced 
genomic methylation indicates disease risk or progression and aberrant DNA 
methylation of specific genes takes part in cardiovascular diseases. One 
research found that the methylation of estrogen receptor (ER)-α promoter could 
increase the severity of atherosclerotic lesions.40 Another article provided 
evidence for dynamic DNA methylation in cardiac hypertrophy, which indicated 
that neonatal rat cardiomyocytes after 7 days of phenylephrine intervention 
exhibited contractile dysfunction and significant inhibition of promoter 
methylation of up-regulated genes associated with hypertrophy.41 One study 
found that DNA methylation-mediated gene expression regulation might play 




5-mC was also reported to be associated with higher mortality in hypertension, 
ischemic heart disease or stroke.43-45 Numerous studies have demonstrated 
that tumor-suppressor genes are silenced by hypermethylation of DNA in the 
promoter region in different cancer types.46 Hypermethylation of the promoter 
regions also plays an important role in the development of colorectal tumors. 47, 
48 Other molecules, such as microRNA (miRNA) and inflammatory factors, 
could also be regulated by DNA methylation in cancers.49, 50 Hypermethylation 
in cancer can often be found in genes with tumor suppressive properties, and 
this epigenetic change has also been observed to affect potential cancer-
promoting gene. While, whether the mechanism of cardiovascular toxicity of 
cancer is associated with DNA methylation is an area worthy of further research 
and discussion. 
The heart pump function, which is critical for blood circulation in the whole 
body, bases on the regular contraction of cardiomyocytes. The cell contraction 
is coupled to the cellular electrical activity. When a myocyte is exited, the 
membrane potential depolarizes from a negative to a positive potential initiating 
the cell contraction and then repolarizes to resting potential leading to cell 
relaxation. The periodical change of membrane potential forms the cardiac 
action potential (AP), which is important for both the rhythm and force of 
cardiomyocyte contraction. The action potential can be divided into five phases, 
which involve contributions of different ion channel currents (Figure1). Phase 0 
is a rapid change in voltage across the cell membrane from a negative resting 
potential to a positive potential, also called a depolarization, lasting less than 
2ms in ventricular cells.51 This change results predominantly from the activation 
of Na+ channel, specifically Nav1.5 channels.52 Phase 1 begins with the rapid 
inactivation of the Na+ channels, which could reduce the Na+ entry. At the same 
time, a rapidly activating K+ channel, the transient outward current (Ito) channel, 
opens shortly, allowing for a brief flow of K+ ions out of the cell, and repolarizing 




potential waveform.53 Phase 2 is also known as plateau period, during which 
the inward currents, mainly the L-type calcium channel current, and outward 
currents, mainly the rapidly activating delayed rectifier K+ current (IKr), are 
similar in strength but in opposite direction. Therefore, the potential change only 
slowly and slightly. During the phase 3 of the action potential, also called the 
“rapid repolarization” phase, the outward K+ channel currents including IKr and 
IKs (the slowly activating delayed rectifier K+ current), largely increased, setting 
the membrane potential back to resting potential. During phase 4 (the resting 
time), the Na+ and Ca2+ ions flowed into cells, and the K+ ions flowed out of 
cells are transported by ion pumps (ATPases) back to their original site. The 
movement of all these ions causes the membrane potential to remain relatively 
constant.54 Furthermore, the inward rectifier potassium current (IK1), which 
activates late in phase 3 and remains conducting throughout phase 4, plays 
also a role in maintaining the resting membrane potential.55 In addition, the 
Na+/Ca2+ exchanger can be activated during the repolarization phase. The 
depolarization velocity (Vmax) of APs predominantly determines the speed of 
excitation conduction. The repolarization velocity mainly determines the 
duration of APs (APD). Dysfunctions of ion channels that contribute to cardiac 
APs may lead to cardiac disorders. For example, loss-of-function of Na+ 
channels cause reduced peak Na+ currents (INa) and Vmax, leading to 
conduction defect, which may cause arrhythmias such as that in Brugada 
syndrome. A loss-of-function of HERG channels causes reduced IKr and 
prolonged APD that is reflected as a long-QT interval in ECG. The long-QT 
interval may result in arrhythmias and therefore is named as long-QT syndrome. 
On the contrary, a gain-of-function of HERG channels enhances IKr and APD 





Figure 1. Schematic diagram of typical action potentials and related currents 
 
For experimental studies on ion channel functions or their roles for human 
cardiac disorders, human cardiomyocytes are an ideal source. However, it is 
very difficult to obtain enough human cardiomyocytes, especially, the 
ventricular cardiomyocytes for experimental studies. As alternatives, animal 
models or animal cells have been employed for studies. Due to the differences 
between animal and human being, animals or animal cells are not ideal for 
mimicking the human cardiac diseases. Besides animal cells, some human cell 
lines, like HEK293 and HeLa cells have been used for some studies 
investigating ion channel functions.56, 57 These non-cardiac cells are not ideal 
for functional studies because they cannot generate action potential and 
contraction. Since the successful reprogramming of adult somatic cells to 
induced pluripotent stem (iPS) cells and generation of functional 
cardiomyocytes from human iPS cells (hiPSC-CM),58-61 hiPSC-CMs have been 
demonstrated to have the electrophysiological properties including action 
potentials which are similar to those of native cardiomyocytes.62, 63 Therefore, 




In summary, more and more evidences suggest a correlation between cancer 
and arrhythmias. However, the effect of cancer cells on the electrophysiology 
of cardiomyocytes is rarely studied. It is unknown whether GI cancer cell 
secretion influences ion channel function of human cardiomyocytes. Here, we 
hypothesize that GI cancer cell secretion may change the electrophysiology of 
human cardiac cells through epigenetic modifications. The aim of the study is 
to use the iPSC-CM platform to examine the possible effects of cancer cell 
secretion on cardiac ion channel functions and investigate the mechanisms of 
effects, mainly focusing on the epigenetic regulation of ion channel gene. The 
results of this study may give insight into mechanisms behind arrhythmias in 






4. MATERIALS AND METHODS 
4.1 The main reagents and instruments 
4.1.1 The main reagents for the experiments 
Table1. Name and company of the reagents.  
Name Company Item number 
DMEM, high glucose, pyruvate Gibco 41966029 
Penicillin-Streptomycin Thermo Fisher Scientific 15140122 
Fetal Bovine Serum Gibco 10500-056 
L-Glutamine Thermo Fisher Scientific 25030024 
0.4% Trypan Blue  Sigma-Aldrich T8154 
Dimethyl Sulfoxide Sigma-Aldrich D2650 
MTT reduction product Synonym Sigma-Aldrich 88417 
TeSR™-E8™ StemCell Technologies 5900 
Matrigel Growth Factor Reduced (GFR) 
Basement Membrane Matrix 
Corning 354230 
0.5 M EDTA Solution AppliChem A4892.0500 
ROCK Inhibitor (Y27632) Miltenyi Biotec 130-095-563 
RPMI Medium 1640 (1X) + GlutaMAX Gibco 61870044 
RPMI 1640 Medium,no glucose, no 
glutamine 
Biological Industries 01-101-1A 
B-27® Supplement (50X), serum free Gibco 17504001 
Ascorbic Acid 2-Phosphate 
Sesquimagnesium Salt Hydrate 
Sigma-Aldrich A8960 
Sodium Pyruvate 100mM Gibco 11360039 
Dimethyl Sulfoxide Sigma-Aldrich D2650 
Recombinant Human/Mouse/rat Activin A R&D Systems  338-AC-010 
Recombinant Human BMP-4 R&D Systems  314-BP-010 
Human FGF-2 Premium Grade Miltenyi Biotec 130-093-841 




Name Company Item number 
IWP-2 StemCell Technologies 72122 
Collagenase I Worthington LS004196 
Trypsin-EDTA 0.05% Gibco 25300054 
Sodium Lactate Solution Sigma-Aldrich 71723 
Hepes 1M Solution  Thermo Fisher Scientific 15630080 
2-Mercaptoethanol (50 mM) Gibco 31350010 
DPBS, no calcium, no magnesium Thermo Fisher Scientific 14190250 
75cm² Cell Culture Flask with Vented Cap Falcon 353136 
24 Well Cell Culture Plate Falcon 353047 
15mL High Clarity PP Centrifuge Tube Falcon 352096 
50mL High Clarity PP Centrifuge Tube Falcon 352070 
35mm Cell Culture Dish Ibidi 81151 
Cell Scrapers Thermo Fisher Scientific 353085 
EMD Millipore Stericup Sterile Vacuum 
Filter  
Thermo Fisher Scientific SCVPU11RE 
Fast Optical 96-Well Reaction Plate, Thermo Fisher Scientific 4346907 
4 Chamber Polystyrene Vessel Tissue 
Culture Treated Glass Slides 
Falcon 354114 
Ethanol Absolut Merck Millipore 107017 
Methanol Absolut Merck Millipore 106009 
Total RNA extraction reagent Qiagen 338112 
High-Capacity cDNA Reverse 
Transcription Kit 
Thermo Fisher Scientific 4368814 
SibirRoxHot Master Mix, ROX 0.1μM   Bioron 119405 
RIPA Puffer Sigma-Aldrich R0278 
Protease Inhibitor Cocktail Sigma-Aldrich P8340 
BCA Protein Assay Kit Thermo Fisher Scientific 23227 




Name Company Item number 
Tris Carl Roth 5429.1 
Sodium dodecyl sulfate, SDS pellets Serva 20765 
Ammonium Persulfate Bio-Rad 1610700 
30 % Acrylamide Carl Roth 3029.1 
TEMED Bio-Rad 1610800 
PVDF Transfer Membrane Merck Millipore GE1060009  
Milchpulver Carl Roth T145.3 
ECL Western Blotting Substrate Thermo Fisher Scientific 32209 
BSA Thermo Fisher Scientific 10270106 
Nitrocellulose Blotting-Membrane PeQlab 39-1010 
Paraformaldehyde 4% Roth P087.4 
Triton X-100 Sigma-Aldrich T-9284 
Proteinase K Qiagen 19131 
Yeast Extract Sigma-Aldrich Y1625 
Tryptone Sigma-Aldrich T9410 
Agarose Sigma-Aldrich A5030 
Ampicillin, sodium salt Thermo Fisher Scientific 11593027 
EpiTect Bisulfite Kits Qiagen 59104 
TaKaRa EpiTaq HS (for bisulfite-treated 
DNA) 
TAKARA R110A 
Wizard SV Gel and PCR Clean-Up System Promega A9281 
DNA Ligation Kit, Mighty Mix TAKARA 6023 
T-Vector  TAKARA 3270 
X-Gal Invitrogen B1690 
Phenol:Chloroform:IAA, 25:24:1 Invitrogen AM9730 
E. coli HST08 Premium Competent Cells TAKARA 9128 
Quick Plasmid Miniprep Kit Thermo Fisher Scientific K210010 




Name Company Item number 
Potassium chloride Sigma-Aldrich P3911 
Calcium chloride Sigma-Aldrich C3881 
Magnesium chloride hexahydrate Sigma-Aldrich MD250 
Glucose Sigma-Aldrich G7528 
HEPEs  Sigma-Aldrich H-3375 
EGTA Sigma-Aldrich E4378 
MyATP Sigma-Aldrich A9187 
Sodium hydroxide Sigma-Aldrich S-5881 
Cesium hydroxide solution Sigma-Aldrich 232068 
Hydrochloric acid Sigma-Aldrich H1758 
Cesium chloride Sigma-Aldrich 289329 
Barium chloride Sigma-Aldrich 449644 
Nickel chloride Sigma-Aldrich 339350 
TEA-Cl Sigma-Aldrich T2265 
Nifedipine Sigma-Aldrich N7634 
Tetrodotoxin                          Roth 6973.1 
E-4031 Sigma-Aldrich M5060 
4-Aminopyridine Sigma-Aldrich 275875 
Chromanol 293B Sigma-Aldrich C2615 
Niflumic acid Sigma-Aldrich N0630 
Lidocaine Sigma-Aldrich L7757 
Dihydroouabain Sigma-Aldrich D0670 









Table2. Primer sequences for real-time polymerase chain reaction (PCR).  
Gene  Gene description Assay ID 
GADPH Glyceraldehyde-3-phosphate dehydrogenase Hs99999905_m1 
SCN5A Nav1.5 Hs00165693_m1 
SCN10A Nav1.8   Hs01045137_m1 
CACNA1C Cav1.2 Hs01062258_m1 
SLC8A1 NCX1 Hs00167681_m1 
KCND3 Kv4.3 (Ito) Hs00542597_m1 
KCNH2 Kv11.1 (hERG /Ikr) Hs04234270_m1 
KCNQ1 Kv7.1, α-subunit of Iks Hs00923522_m1 
KCNJ2 Inward rectifier K+ channel Kir2.1 Hs00265315_m1 
4.1.2 The main instruments for the experiments 
Table3. Name and company of the instruments 
Name Company                
Cytometry plate BRAND  
Pipetus Eppendorf  
Centrifuge M&S Laborgerate GMBH 
Incubator Thermo HeRacell 240 
Thermostat Memmert  
Microscope Leica DMIL  
Fluorescence microscope Leica DMRE DFC3000G 
PCR Amplifier PeQSTAR PeQlab 
qPCR Applied Biosystems stepone Plus 
Microplate Readers Tecan infinite m200 
Electrophoresis Chambers BIO-RAD  
The ChemiDoc MP Imaging System PeQlab  
Patch electrodes World Precision Instruments MTW 150F 
DMZ-Universal Puller Zeitz-InstrumenteVertriebs GmbH 




4.2 Experimental methods  
4.2.1 Study design 
To investigate the cardiac effects of cancer secretion in hiPSC-CMs, especially 
the GI cancers, the stomach and colon cancer cells were adopted. Considering 
the importance of cell numbers and cell growth time for the concentration of 
components secreted by cultured cancer cells, we tried to generate the growth 
curve by manual cell counting and MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay. The number of seeding cancer cells was 
fixed (1x105) and the culture media (for studies investigating the effects of 
components secreted by cancer cells) were collected when the cancer cells 
grew to a plateau-phase. For the treatment of cardiomyocytes, conditioned 
cancer cell media were 10%, 20%, 40%, and 80% diluted in fresh cardio culture 
medium for cardiomyocytes. As conditional control groups, the fresh culture 
medium for cancer cells, which was not cultured with cancer cells and used as 
a medium control, was also added in cardiomyocyte culture medium at the 
same percentages (10%, 20%, 40%, and 80%). Then after 48h, the 
cardiomyocytes were collected for following experiments. The specific group 
information and experiment design are described in Figure 2. 
To determine whether the cancer cell secretion changes action potential 
parameters and ion channels responsible for APs, action potentials and 
different ion channel currents including Na+, Ca2+, K+, Na+/Ca2+ exchanger were 
recorded by patch clamp whole cell recording technique in hiPSC-CMs treated 
with cultured or non-cultured (medium control) cancer cell medium to examine 
effects of cancer cell secretion. Meanwhile, the expression of the respective ion 
channels was assessed by qPCR and western blotting at mRNA and protein 
level.  
To identify possible mechanisms of cancer secretion on the 
electrophysiology of hiPSC-CMs, the possible epigenetic regulation of cancer 




whole genome methylation level was measured by dot blotting and the protein 
levels of DNMTs (for DNA methylation) and TET1 (for DNA demethylation) were 
detected by western blotting. Then the DNA methylation level of CpG sites in 
gene promoter was investigated by bisulfite sequencing polymerase chain 
reaction. Next, the effect was confirmed by overexpression of TET1. After 
overexpression of TET1, the ion channel currents were again assessed to 
further confirm the epigenetic regulation of ion channels by cancer secretions. 
 
Figure 2. Study design. “Ctr” represents hiPSC-CMs without medium for cancer cells. 




(medium control). “AGS” represents hiPSC-CMs with addition of cultured medium of AGS 
cancer cells. “SW480” represents hiPSC-CMs with addition of cultured medium of SW480 
cancer cells. 
 
4.2.2 Cancer cell culture 
The two cancer cell lines AGS and SW480 were gifts from Dr. Isabel 
Hinsenkamp and Dr. Elke Burgermeister from Department of Internal Medicine 
II of the Medical Faculty Mannheim. The detailed information is listed as 
followed: 
(1) AGS (ATCC® CRL-1739™) comes from stomach 
https://www.lgcstandards-atcc.org/Products/All/CRL-1739.aspx 
(2) SW480 [SW-480] (ATCC® CCL-228™) comes from colon 
https://www.lgcstandards-atcc.org/Products/All/CCL-228.aspx 
Cancer cells (1 × 105 cells) were seeded in T75 flasks, and then cultured in 
DMEM (10mL) supplemented with 10% FBS and 1% Pen/Strep. The medium 
was changed every 2 days until reaching the plateau-phase, at which the total 
number of AGS and SW480 cancer cells in a T75 flask increased to about 
4.0X106 and 7.7X106 respectively.  
4.2.3 Differentiation and culture of hiPSCs   
The hiPSCs were generated from primary healthy donor fibroblasts derived 
from skin biopsies in the department of dermatology, university medical center 
Mannheim. The hiPSCs were maintained in E8 medium (StemCell 
Technologies) supplemented with human albumin and ascorbic acid. Then the 
directed differentiation of hiPSCs into cardiomyocytes (hiPSC-CMs) was 
initiated at 80–90% confluence in 24-well plates with Matrigel coated. The 
cardio differentiation medium composed of RPMI 1640 with Glutamax and 
HEPES (Thermo Fisher Scientific), 2% B27 (Thermo Fisher Scientific), 
0.2mg/ml L-ascorbic acid 2-phosphate (Sigma-Aldrich), 1% Sodium Pyruvate 




the hiPSCs were sequentially treated with 1μM CHIR99021 (StemMACS), 
5ng/ml BMP4 (R&D Systems), 9ng/ml activin A (R&D Systems), 5ng/ml FGF 
(Miltenyi Biotec) for 3 days and then 5μM IWP2 (StemCell Technologies) for 
about 8-10 days with the cardio differentiation medium. Differentiated cells were 
glucose-starved and supplemented with 5mM Sodium Lactate Solution (Sigma-
Aldrich), 50mM 2-mercaptoethanol (Gibco) with RPMI 1640 without glucose nor 
glutamine to metabolically select hiPSC-CMs around day 13-15. The iPSC-
CMs were cultured in maintenance media at least to day 50-60 for further 
maturation. The successful differentiation of hiPSC-CMs was confirmed by 
immunofluorescence of cardiac markers α-actinin and myosin light chain 4 
(Myl4) (figure 3). Cardiomyocytes were dissociated from 24-well plates for 
biological studies or plated on Matrigel-coated 3.5cm petri dishes for patch-
clamp measurements. For preparing the single cell from 24-well plate to dishes, 
the flowing steps were performed: 
(1) We put 300μl collagenase in PRMI1640 medium in every well, then the cells 
were incubated at 37 °C for 40min. 
(2) 1ml pipette was used to pipette un and down 10 times of cell suspension. 
(3) Then the cell suspension was centrifuged at 250g, at room temperature for 
2min, and the supernatant aspirated. 
(4) The cell precipitation was washed with DPBS (no calcium, no magnesium), 
again centrifuged at 250g, at room temperature for 2min, and the 
supernatant was aspirated. 
(5) Then 300μl 0.05%trypsin was added to the tube, then pipetted up and down 
10 times, incubated at 37 °C for 2min. 
(6) For stopping the reaction, we added 300μl PRMI 1640 medium and 10% 
FCS, centrifuged the cell suspension at 250g at room temperature for 2min, 




(7) To resuspend the cells, cardio differentiation medium was added, pipetted 
up and down 10 times with 10ml pipette, and then the cell suspension was 
added to dishes. 
 
Figure.3 Immunostaining of human induced pluripotent stem cell–derived 
cardiomyocyte (hiPSC-CM) marker of different groups. Shown is the expression of α-
actinin (red) and Myl4 (green) in hiPSC-CMs. “Ctr” represents hiPSC-CMs without medium 
for cancer cells. “Medium” represents hiPSC-CMs with addition of un-cultured medium for 
cancer cells. “AGS” represents hiPSC-CMs with addition of cultured medium of AGS 
cancer cells. “SW480” represents hiPSC-CMs with addition of cultured medium of SW480 
cancer cells. Scale bars, 20 μm. 
 
4.2.4 Manual cell counting and MTT assay 
Manual cell counting was carried out with a hemocytometer and a microscope, 
using 0.4%trypan blue-treated cell suspension. The number of cells in all 4 
outer squares were counted and then divided by 4 (the mean number of cells 
per square). The number of cells per milliliter of suspension equaled to the 




MTT assay is a quantitative colorimetric method, which allows evaluation of 
cell viability and proliferation, and cytotoxicity of different compounds. The 
method is based on enzyme reduction of MTT tetrazolium salt (3-(4,5-
dimethylthiazolyl)-2,5-diphenyltetrazolium bromide) to its dark blue insoluble 
formazan. The hiPSC-CMs around day 50-60 were seeded in 96-well plates (5 
× 103 cells per well) and cultured for 12h in a cell incubator. Then different 
concentration of cancer cell media was added for another 48h. The hiPSC-CMs 
added with fresh cardio culture media were used as a negative control. Then 
20μL MTT (5 mg/mL in PBS, Sigma-Aldrich) were added to each well. After 4h 
incubation, the supernatant was replaced with 150μL of DMSO solution (Sigma-
Aldrich). Absorbance OD was measured at 490nm and cell viability is 
calculated. 
4.2.5 Polymerase chain reaction assays 
PCR-analyses were carried out to assess the ion channel expression at mRNA 
level in hiPSC-CMs. hiPSC-CMs were dissected and extracted for total RNA 
with RNAiso Plus (Total RNA extraction reagent) (Qiagen, Hilden, Germany). 
The cDNA synthesized from total RNA was amplified by qPCR on the Real-
time PCR System (Applied Biosystems 7500 Real-Time PCR Systems) using 
a PCR mix with hot start Taq DNA polymerase and SYBR Green (Sibir Rox Hot 
Mastermix, Catnumber 119405, BIORON, Germany) in the presence of sense 
and antisense primers (400nM each). The relative expression levels of each 
mRNA were calculated as the gene of interest relative to GAPDH which was 
calculated by the ΔΔCT method, based on the threshold cycle (CT), as fold 
change = 2−Δ(ΔCT), where ΔCT = CTgene of interest - CT GAPDH and Δ(ΔCT) =ΔCTcancer 
cell medium − ΔCTcontrol. 
4.2.6 Patch-clamp 
The hiPSC-CMs plated on Matrigel-coated 3.5cm petri dishes were used for 
the following patch-clamp measurements. All the experiments of action 




cell patch clamp recording techniques and carried out at room temperature (22-
25° C). Patch electrodes we used were borosilicate glass capillaries (MTW 
150F; world Precision Instruments, Inc., Sarasota, FL) and were pulled with 
DMZ-Universal Puller (Zeitz-InstrumenteVertriebs GmbH, Martinsried, 
Germany) and filled with pre-filtered pipette solution. The pipette resistance 
ranged from 1–2 MΩ for measurements. To isolate one type of ion channel 
current from other types of channels, a specific channel blocker or solution was 
used. Recording was started when the current stabilized (usually within 3 to 5 
minutes). In order to examine the cell capacitance, a voltage pulse from −70 to 
−75mV was given for recording the capacitance transient current. Then the 
area under transient current curve was calculated and divided by 5 mV to get 
the whole cell capacitance in pF, which was used for calculating current density. 
Resting and action potentials  
With the current-clamp techniques without stimulation (CC-mode), the resting 
membrane (RP) potential was recorded. For measuring APs paced at a fixed 
frequency, if the RP was more positive than -70mV, negative currents (-10 to -
50pA) was injected into the cell to keep the RP at -70 to -75mV. Then action 
potential (AP) was provoked to pulse stimulations (1nA for 5ms) at 0.5Hz, 1Hz, 
2Hz, and 3Hz. The effects of cancer cell secretion on APS in different groups 
were assessed.  
Membrane currents 
By voltage-clamp techniques, membrane currents were measured at whole-
cell level. Cardiomyocytes express many types of ion channels in plasma 
membrane, which are important for the normal functions of the cells. The 
electrophysiological properties of different ion channel currents in hiPSC-CMs 
cultured with cancer cell media were characterized and compared with those 
cultured without cancer cell medium. Recordings were started when the current 
became stable, usually within 3 to 5 minutes. To assess the effects of cancer 




including the activation, inactivation, and recovery from inactivation of the peak 
sodium current (INa), the L-type calcium channel current (ICa-L) and  Na+-Ca2+ 
exchanger current (INCX), the transient outward K+ current (Ito), the inward 
rectifier potassium current (IK1), the slowly activating delayed rectifier potassium 
channel current (IKs) and the rapidly activating delayed rectifier potassium 
channel current (IKr) were analyzed. Currents were sampled and analyzed by 
an ISO-3 multitasking patch-clamp program (MFK M. Friedrich, Niedernhausen, 
Germany). The whole-cell currents were measured at the peak or end of each 
pulse and normalized to cell capacitance to obtain the current density (pA/pF). 
The density was plotted versus the respective voltages, yielding the activation 
(I/V) curves of channels in the cell. The membrane conductance (Gm) was 
calculated as Gm = I/ (Em− Erev). I is macroscopic current, Em is the test 
membrane potential, and Erev is the reversal potential. Gm values were plotted 
against test voltages to obtain conductance-voltage (G/V) curves. 
Solutions for patch clamp measurements 
For AP measurements, the isotonic solution contained 130mmol/L NaCl, 
5.9mmol/L KCl, 1.2mmol/L MgCl2, 2.4mmol/L CaCl2, 11mmol/L glucose, and 
10 mmol/L HEPES (pH 7.4 (NaOH)). The pipette solution contained 20mmol/L 
KCl, 110mmol/L K-aspartate, 1mmol/L MgCl2, 0.5mmol/L EGTA, 2mmol/L ATP, 
0.5mmol/L GTP, and 10mmol/L HEPES (pH 7.2 (KOH)). 
For peak sodium current (INa) measurements, the bath solution contained 
20mmol/L NaCl, 110mmol/L CsCl, 1.8mmol/L CaCl2, 1mmol/L MgCl2, 
10mmol/L HEPES, 10mmol/L glucose, and 0.001mmol/L nifedipine (pH 7.4 
(CsOH)). Microelectrodes were filled with 10mmol/L NaCl, 135mmol/L CsCl, 
2mmol/l CaCl2, 3mmol/L MgATP, 2mmol/L TEA-Cl, 5mmol/L EGTA, and 
10mmol/L HEPES (pH 7.2 (CsOH)). 
The bath solution for L-type calcium channel current (ICa-L) recordings 
contained 140mmol/L TEA-Cl, 5mmol/L CaCl2 , 1mmol/L MgCl2, 10mmol/L 




(CsOH)). The pipette solution contained 10mmol/L NaCl, 135mmol/L CsCl, 
2mmol/L CaCl2, 3mmol/L MgATP, 2mmol/L TEA-Cl, 5mmol/L EGTA, and 
10mmol/L HEPES (pH 7.2 (CsOH)). 
The bath solution for Na+-Ca2+ exchanger current (INCX) measurements 
contained 135mmol/L NaCl, 10mmol/L CsCl, 2mmol/L CaCl2, 1mmol/L MgCl2, 
10mmol/L HEPES, 10mmol/L glucose, 0.01mmol/L nifedipine, 0.1mmol/L 
niflumic acid, 0.05mmol/L lidocaine, and 0.02mmol/L dihydroouabain (pH 7.4 
(CsOH)). Microelectrodes were filled with 10mmol/L NaOH, 150mmol/L CsOH, 
2mmol/L CaCl2, 1mmol/L MgCl2, 75mmol/L aspartic acid, and 5mmol/L EGTA 
(pH 7.2 (CsOH)). 
For measuring K+ channel currents, the bath solution contained 130mmol/L 
NaCl, 5.9mmol/L KCl, 2.4mmol/L CaCl2, 1.2mmol/L MgCl2, 11mmol/L glucose, 
and 10mmol/L HEPES (pH 7.4 (NaOH)). The pipette solution contained 126mM 
KCl, 6mM NaCl, 1.2mM MgCl2, 5mM EGTA, 11mM glucose, 10mM HEPES, 
and 1mM MgATP (pH 7.4 (KOH)). For the transient outward K+ current (Ito) 
measurements, 10μM nifedipine, 10μM TTX, and 3μM E-4031 were added in 
the bath solution to block ICa-L, INa, and IKr, respectively. For the inward rectifier 
current (IK1) measurement, 10μM nifedipine and 3μM E-4031 were added. For 
the slowly activating delayed rectifier K+ (IKs) measurements, 10μM nifedipine, 
3mM 4-AP, and 10μM TTX were added.  
To improve the measurement of the rapidly activating delayed rectifier 
channels (IKr), the Cs+ instead of K+ ions were used as the charge carrier. 
External solution for Cs+ current measurements contains 140mmol/L CsCl, 
2mmol/L MgCl2, 10mmol/L HEPES, and 10mmol/L glucose (pH 7.4 (CsOH)). 
Pipette solution contained 140mmol/L CsCl, 2mmol/L MgCl2, 10mmol/L HEPES, 
and 10mmol/L EGTA (pH 7.2 (CsOH)). 
4.2.7 Western blotting 
The ion channel expression at protein level was assessed by western blotting 




Merck KGaA, Darmstadt, Germany). The lysate was centrifuged at 12,000 × g 
for 10min at 4 ºC. Then the supernatant fraction was collected for Western 
blotting analysis. BCA Protein Assay Kit (23227; Thermo Fisher Scientific, 
Waltham, MA, USA) was used to detect the protein concentration and all the 
concentration of samples were diluted to 1μg/μl with RIPA buffer. The protein 
samples were loaded 10ug per sample for SDS-PAGE, and then transferred to 
the PVDF membrane (IPVH00010, Immobilon-p, Merck KGaA, Darmstadt, 
Germany). Then the membranes were blocked with 5% nonfat milk in tris-
buffered salt solution with tween (TBST) for 1h at room temperature. After 
blocking, the membranes were incubated with the primary antibodies at 4˚C 
overnight. The primary antibodies used in western blotting analysis were as 
follow: Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (14C10) 
antibody (2118S, 1:10000; Cell Signaling, Chicago, IL, USA); anti-Nav1.5 
(SCN5A)(493-511) antibody (ASC-005, 1:500; Alomone Labs, Israel); anti-
Cav1.2 (CACNA1C) antibody (ASC003, 1:500; Alomone Labs, Israel); anti-
NCX1 antibody (ab135735, 1:500; Abcam, Cambridge, UK); anti-Kv4.3 (KCND3) 
antibody (APC-017, 1:500; Alomone Labs, Israel); anti-hKv11.1 antibody 
(P9497, 1:400; Sigma-Aldrich, Merck KGaA, Darmstadt, Germany); anti-
KCNQ1 antibody (APC-022, 1:500; Alomone Labs, Israel); anti-Kir2.1/BIK 
antibody (ab109750, 1:1000; Abcam, Cambridge, UK); DNMT1 antibody 
(NB100-56519, 1:5000; Novus Biologicals, USA); DNMT2 antibody (19221-1-
AP, 1:1000; ProteinTech, IL, USA); DNMT3A antibody (NB120-13888, 1:2000; 
Novus Biologicals, USA); DNMT3B antibody (NB300-516, 1:500; Novus 
Biologicals, USA); anti-TET1 antibody-C-terminal (ab101698, 1:1000; Abcam, 
Cambridge, UK). The secondary antibodies were anti-rabbit IgG-peroxidase 
produced in goat (A0545, 1:2000; Sigma-Aldrich, Merck KGaA, Darmstadt, 
Germany) or anti-mouse IgG-peroxidase produced in goat (A3682, 1:2000; 
Sigma-Aldrich, Merck KGaA, Darmstadt, Germany). The target protein bands 




software (AlphaView, Protein Simple, California, USA) for statistical analyses 
in all groups. 
 
Table 4. The detail information of the gel involved in the western blotting. 
Separating gel 8% /mL 10% /mL 12% /mL Stacking gel  
ddH2O 4.6 4 3.3 ddH2O 2.8 
1.5M Tris pH8.8 2.5 2.5 2.5 0.5M Tris pH6.8 1.25 
10%SDS 0.1 0.1 0.1 10%SDS 0.05 
10%APS 0.1 0.1 0.1 10%APS 0.05 
Acrylamide 2.7 3.3 4 Acrylamide 0.85 
TEMED 0.008 0.008 0.008 TEMED 0.005 
 
4.2.8 Immunofluorescence  
The localization of cellular expression of ion channel proteins was determined 
by immunofluorescence staining. Cardiomyocytes were dissociated from 24-
well plates and plated onto the culture slides (354114; Thermo Fisher Scientific, 
Waltham, MA, USA). After incubated with cancer cell media or cardio culture 
medium for 48h, all slides were fixed with 4% paraformaldehyde at room 
temperature for 10min and permeabilized with 0.5% triton for 10min. After 
blocking with 5% bovine serum albumin (BSA, 10270106; Thermo Fisher 
Scientific, Waltham, MA, USA) for 30min, the slides were incubated with 
primary antibodies at 4˚C, and then were incubated with the second antibodies 
anti-rabbit/mouse IgG (H+L), F(ab')2 Fragment (1:2000; Cell Signaling, USA). 
The primary antibodies used on hiPSC-CMs were monoclonal anti-α-actinin 
(Sarcomeric) (A7811, 1:200; Sigma-Aldrich, Merck KGaA, Darmstadt, 
Germany); anti-Myl4 antibody (A20170301415, 1:200; Cloud-Clone corp, CCC, 
USA); anti-Nav1.5 (SCN5A)(493-511) antibody (ASC-005, 1:500; Alomone 
Labs, Israel); anti-Kv4.3 (KCND3) antibody (APC-017, 1:500; Alomone Labs, 




random fields per wells (at least 10 cells) were photographed, and the 
immunofluorescence density of the positive staining per field was measured by 
Image-Pro Plus software (Media cybernetics, Acton, MA, USA). 
4.2.9 Genomic DNA extraction 
Extraction of DNA by phenol chloroform method: 
(1) First we put different groups of cells in 1.5ml Ep tubes, added 500μl of SNET 
solution (20mM Tris-HCl 0.121g，5mM EDTA 0.093g，400mM NaCl 1.17g， 
SDS 0.5g，add ddH2O to 50ml), 10μl of proteinase K. Then we incubated 
the tubes in water bath at 55°C overnight. 
(2) Next day we added 500μl of PCI solution (phenol: chloroform: isoamyl 
alcohol = 25:24:1) to the lower layer of liquid and mixed gently until the 
mixture is homogeneous. 
(3) Then we centrifuged the tubes at 15000 rpm for 15 min at room temperature. 
The supernatant was loaded to a new Ep tube (about 400μl), an equal 
volume of isopropanol (400μl) was added. Then we mixed the liquid by 
inverting the tubes. 
(4) Again, centrifuged the tubes at 15000 rpm for 8 min at room temperature, 
discarded the supernatant, added 70% ethanol to wash and then 
centrifuged the tubes at 15000 rpm for 5-7 min at room temperature. 
(5) Then we discarded the supernatant. The DNA was dried for 5~10min. Then 
we added 30μl ddH2O to every tube, to dissolve the genomic DNA. 
4.2.10 Dot blotting 
Dot blotting is a simple technique for immobilizing bulk unfractionated DNA on 
a nitrocellulose or nylon membrane. Hybridization analysis can then be carried 
out to determine the relative abundance of target sequences in the blotted DNA 
preparations. Genome DNA was extracted from hiPSC-CMs treated with or 
without cancer cell media by using phenol-chloroform extraction. The genome 
DNA was serially diluted and denatured in 0.1M NaOH/10 mM EDTA at 100˚C 




nitrocellulose membrane) and air-dry. The membrane was washed with 20 × 
SSC buffer (175.3g NaCl, 88.2g trisodium citrate, pH 7.0 in 1L ddH2O) and then 
soaked in denaturation solution (1.5M NaCl, 0.5M NaOH) for 10min, then in 
neutralization solution (1M NaCl, 0.5M Tris-HCl pH 7.0) for 5min. Then the 
membrane was baked for 2h at 80˚C. After blocking the membrane with 5% 
nonfat milk in TBST for 1h at room temperature, the membrane was incubated 
with anti-5-methylcytidine antibody (ab10805, 1:5000; Abcam, UK) and 
recombinant anti-5-hydroxymethylcytosine (5-hmC) antibody [RM236] 
(ab214728, 1:1000; Abcam, UK) at 4℃ overnight. The secondary antibodies 
are anti-mouse IgG, HRP-linked antibody (7074, 1:2000; Cell Signaling, 
Chicago, IL, USA). The dots were detected and quantified by Fusion Solo 
system (Vilber, France). 
4.2.11 Bisulfite sequence 
Genomic DNA bisulfite (BSP) conversion is to convert the unmethylated 
cytosines from cytosine (C) to uracil (U), while methylated cytosine cleavage is 
unchanged and remains C. The BSP primers are designed for PCR 
amplification in the target region. After expansion, U is converted to thymidine 
cleavage (T), while the CpG site of methylation in the extended sequence is still 
C, and the unmethylated CpG site is T. The PCR product is expanded, and 
after delivery, it is judged that some CpG sites are methylated. The bisulfite 
conversion of genome DNA from different groups was performed with EpiTect 
Bisulfite Kits (59104, QIAGEN, Germany). Specific steps were as follow: 
(1) The extracted genomic DNA was diluted. Then we added 800μl of RNase-
free water to the required number of Bisulfite Mix powder tubes, and 
vortexed until the Bisulfite Mix was completely dissolved (concussive for 
5min). If the dissolution was not homogeneous, it was heated to 60 ° C and 
then shook again. 
(2) Then the BSP reaction system was added to a 200μl PCR tube containing 




Bisulfite Mix 85μl, DNA Protect Buffer 35μl, total 140μl. They were mixed 
until DNA Protect Buffer changed from green to blue in the system. 
(3) The reaction was carried out under the following conditions: 95 ° C for 5min; 
60 ° C for 25min; 95 ° C for 5min; 60 ° C for 85min; 95 ° C for 5min; 60 ° C 
for 175min; totally about 5h. 
(4) After the reaction was completed, we centrifuged the tubes, and transferred 
the reaction system into a 1.5ml Ep tube. 
(5) Then we added 560μl of configured Buffer BL to each reaction system 
(before using, we have already added carrier RNA at a final concentration 
of 10μg/ml to Buffer BL). 
(6) The EpiTect spin columns were put in the collection tube, and the system 
from step (5) was transferred into the EpiTect spin columns, centrifuged at 
maximum speed for 1min. Then we discarded the flowthrough in the 
collection tubes and placed the EpiTect spin columns in the collection tubes. 
(7) Then 500μl Buffer BW was added to each tube and centrifuged at maximum 
speed for 1min.Then we discarded the flowthrough in the collection tubes 
and placed the EpiTect spin columns back in the collection tubes. 
(8) Next, we added 500μl Buffer BD to each tube. The tubes were incubated 
for 15min at room temperature, then centrifuged at maximum speed for 
1min. We discarded the flowthrough in the collection tubes and placed the 
EpiTect spin columns in the collection tubes. 
(9) Again, we added 500μl Buffer BW to each tube, centrifuged the tubes at 
maximum speed for 1min, discarded the flowthrough in the collection tubes, 
and placed the EpiTect spin column in the collection tube again, repeating 
this step again. 
(10) Next, we placed the EpiTect spin columns in new collection tubes and 




(11) Then we placed the EpiTect spin columns in new 1.5ml Ep tubes and 
placed 20μl Buffer EB into the center of the EpiTect spin columns. The BSP-
DNA solution was collected by centrifugation at 15,000 x g for 1min. 
4.2.12 Sequencing polymerase chain reaction 
The promoter sequences were searched on UCSC Genome Browser 
(https://genome.ucsc.edu/). Bisulfite sequencing polymerase chain reaction 
(PCR) primers for CpG islands were designed by using Methyl Primer Express 
v1.0 software (Thermo Fisher Scientific, USA). PCR amplification was 
performed using TaKaRa EpiTaq HS (for bisulfite-treated DNA) kit (purchased 
from TAKARA, product number R110A) containing:  
(1) TaKaRa EpiTaq HS (5 U/μl) 0.25μl, 10× EpiTaq PCR Buffer (Mg2+ free) 5μl, 
25mM MgCl 25μl, dNTP Mixture (2.5 mM each) 6μl, BSP-DNA <100 ng, 20 
pmol each of the upstream and downstream primers, and ddH2O to 50μl. 
(2) Reaction conditions: 98 ° C for 1min; (98 ° C for 10 s, 50 ° C for 30 s, 98 ° 
C for 30 s) × 40; 72 ° C for 10min. The BSP primer sequences of ion 
channels detected are shown in Table 5.  
Table 5. Bisulfite sequencing PCR primers for CpG islands 
 Primer 5' to 3' Products 













4.2.13 PCR products purification 
After the reaction was completed, 1.5% agarose gel was adapted, and 120V 
electrophoresed for about 1 hour. The gel imager was exposed, and the gel 




gel electrophoresis and purified using Wizard SV Gel and PCR Clean-Up 
System (A9281/2/5, Promega, USA): 
(1) First for dissolving the Gel slices, we excised DNA band from gel and placed 
gel slices in 1.5ml microcentrifuge tubes. 
(2) Then we added 10μl Membrane Binding Solution per 10mg of gel slice. The 
gel slices were vortexed and incubated at 50-65 °C until them were 
completely dissolved. 
(3) Next, we inserted SV Minicolumns into Collection Tubes. 
(4) Then we transferred the dissolved gel mixture or prepared PCR product to 
the Minicolumn assembly and incubated at room temperature for 1min. 
(5) The tubes were centrifuged at 16,000 X g for 1min. Then we discarded the 
flowthrough and reinserted Minicolumns into Collection Tubes. 
(6) All the tubes were added 700μl Membrane Wash Solution with ethanol. And 
centrifuged at 16,000 X g for 1min. Then we discarded the flowthrough and 
reinserted Minicolumns into Collection Tubes. 
(7) Again, we added 500μl Membrane Wash Solution with ethanol to the tubes 
and centrifuged them at 16,000 X g for 5min. 
(8) Next, we discarded the flowthrough and placed the columns back into the 
wash tubes and recentrifuged the column at 16,000 X g for 1min. 
(9) Then we transferred Minicolumns to clean 1.5ml microcentrifuge tubes. 30μl 
of Nuclease-Free Water was added to the Minicolumns and incubated at 
room temperature for 1min, and then centrifuged at 16,000 X g for 1min. 
(10) At last, we discarded the Minicolumns and tested the concentration of 
samples. 
4.2.14 Plasmid ligation and amplification 
The purified PCR products were inserted into pMD20-T vector with TaKaRa 
Mighty TA-cloning Kit (6028, Takara, Shiga, Japan) and transformed to E. coli 
HST08 Premium Competent Cells (9128, Takara, Shiga, Japan) for sequencing 




CpG site within the region amplified was determined by online software 
(http://services.ibc.uni-stuttgart.de/BDPC/BISMA/). 
Plasmid ligation was performed as follows: 1μl of the above purified DNA, 1μl 
of pMD20-T vector, 3μl of ddH2O, 5μl of Ligation Mighty Mix, reaction at 16 ° C 
for 30 minutes. The whole amount of E. coli HST08 Premium Competent Cells 
(purchased from TAKARA, Cat. No. 9128) was added for conversion as follows: 
(1) E. coli HST08 Premium Competent Cells were thawed on ice before using, 
and 100μl of cells were added to a 15 ml round bottom Falcon tube.  
(2) Then we added DNA samples (≤10ng), placed them in ice for 30min, then 
at 42°C for 45s, then placed in ice for 1-2 minutes. 
(3) Next, we added 37°C pre-warmed SOC medium to 1ml, shook the culture 
at 37°C for 1h (160~225rpm).  
(4) An appropriate amount (100μl) was applied to the LB solid medium (the 
medium was added to the final concentration of 100μg/ml of ampicillin). 
(5) X-gal (20mg/ml) 40μl was applied to the plate 1 to 2 min before using. 
(6) Then we cultured them overnight at 37 °C. 
(7) After the colonies were grown, white colonies were picked, shaken 
overnight at 37 °C in LB liquid medium, then centrifugated at 220 rpm/min. 
4.2.15 Plasmid extraction  
To follow this procedure to purify plasmid DNA we used a centrifuge. 
(1) First, we centrifuged 1-5ml of the overnight LB-culture and removed all 
medium. 
(2) Then 250μl Resuspension Buffer with Rnase A was added to the cell pellets 
and the pellets were resuspended until they were homogeneous. 
(3) We added 250μl Lysis Buffer to the tubes, mixed them gently by inverting 
the capped tubes until the mixture was homogeneous, without vortex. Then 




(4) 350μl Precipitation Buffer was added per tube, mixed immediately by 
inverting the tube until the mixture was homogeneous, without vortex. Then 
the lysate was centrifuged at >12,000 X g for 10min. 
(5) We loaded the supernatant from step (4) onto a spin column in the 2ml wash 
tubes，again centrifuged the columns at 12,000 X g for 1min. Then we 
discarded the flowthrough and placed the column back into the wash tubes. 
(6) 500μl Wash Buffer with ethanol was added to every column. Then we 
incubated the columns for 1min at room temperature， centrifuged the 
columns at 12,000 X g for 1min. Then we discarded the flowthrough and 
placed the columns back into the wash tubes. 
(7) Next, we added 700μl Wash Buffer W9 with ethanol to every column， 
centrifuged the columns at 12,000 X g for 1min and discarded the 
flowthrough, emptied the columns and placed the columns back into the 
wash tubes，again centrifuged the column at 12,000 X g for 1min. Then 
discarded the wash tube with flowthrough. 
(8) Then we placed the Spin Column in the clean 1.5ml collection tubes. 50ul 
TE Buffer was added to the center of the columns. And we incubated the 
columns for 1min at room temperature. 
(9) Again, we centrifuged the columns at 12,000 X g for 2min. The collection 
tubes contained the purified plasmid DNA. So, we discarded the columns 
and detected the concentration of plasmid DNA. 
4.2.16 Overexpression of the ten-eleven translocation family enzymes 
The overexpression of TET1 gene was accomplished by transfection of TET1 
plasmid FH-TET1-pEF. This plasmid expressed the full-length human TET1 
gene. An empty backbone plasmid pEF1a-IRES-Neo was used as the empty 
control. FH-TET1-pEF was a gift from Anjana Rao (Addgene plasmid # 49792; 
http://n2t.net/addgene:49792; RRID:Addgene_49792) and pEF1a-IRES-Neo 
was a gift from Thomas Zwaka (Addgene plasmid # 28019; 




was performed by using FuGENE® HD Transfection Reagent (E2311, Promega, 
WI, USA) according to the protocol provided by Promega. Briefly, we added for 
each well 1μg plasmid DNA to the Opti-MEM® medium and mixed well and 
added 3μl FuGENE® HD Transfection Reagent (3:1 FuGENE® HD Transfection 
Reagent: DNA) and mixed well immediately. The mixture was incubated for 
5min in room temperature. Then added 25μl of the mixture was added to each 
well of 24-well plate and mixed by pipetting. The cells were incubated for 2 days. 
4.2.17 Statistics 
All data analyses were performed by an experienced technician who had no 
understanding of experimental grouping details and results. All statistical data 
were expressed as mean ± standard error of the mean values (SEM). Statistical 
analyses were performed by GraphPad Prism 7 (GraphPad Software Inc., 
California, USA). Student’s t-test, one-way analysis of variance (ANOVA), and 
two-way ANOVA with Dunnett’s multiple comparisons post-test were applied. 
P values less than 0.05 are statistically significant. The n values in each figure 
legend reflect the number of cells used for the statistical analysis. 
4.2.18 Ethics statements 
This project was conducted in accordance with the ethical principles that have 
their origin in the Declaration of Helsinki. The generation and application of 
hiPSC-CMs have been approved by the Ethics Committee of Medical Faculty 













5.1 Culture medium for cancer cells had no effect on the growth of hiPSC-
CMs 
Considering that the number of cancer cells in a flask was critical for the 
concentration of cell secretions in the culture medium that were taken for the 
study, cancer cell growth rate analyses of the two cancer cell lines (AGS and 
SW480) were performed by manual cell counting and MTT assay. The curves 
displayed that the growth of both cancer cell lines reached a maximum at day 
8 of culture when AGS and SW480 cancer cells in a T75 flask increased to 
about 4.0X106 and 7.7X106 respectively. (Figure 4A, B). So, the cancer cell 
medium cultured for 8 days with same seeded number of cells was used for all 
experiments in this study.  
Because different medium is required for culture of cancer cells and hiPSC-
CMs, the cancer cell medium, when it was added into culture medium of hiPSC-
CMs, may interfere the growth of hiPSC-CMs. Therefore, we checked the effect 
of non-cultured medium (for control) and different concentrations of medium 
cultured with same amount of cancer cells on the growth of hiPSC-CMs. The 
cancer cell medium was added into culture dishes with cardiomyocytes in four 
different concentrations, 10% (v/v), 20%, 40% and 80%, respectively. As shown 
in Figure 4C and D of the MTT assay, we found that different concentration of 
the medium with (AGS or SW480) or without (medium) cancer cells showed no 





Figure 4. Cancer cell medium had no effect on cell growth of hiPSC-CMs. (A) Cell 
growth curve by cell counting. (B) Cell growth curve by MTT assay. (C, D) Cell viability of 
hiPSC-CMs under different concentrations of supernatant of AGS and SW480 cell culture 
and medium without cancer cells. “Ctr” represents data from hiPSC-CMs without medium 
for cancer cells. “Medium” represents data from hiPSC-CMs with addition of un-cultured 
medium for cancer cells. “AGS” represents data from hiPSC-CMs with addition of cultured 
medium of AGS cancer cells. “SW480” represents data from hiPSC-CMs with addition of 
cultured medium of SW480 cancer cells. Data are presented as mean ± SEM and analyzed 
by one-way ANOVA. 
 
5.2 Effects of cancer cell secretion on action potentials of hiPSC-CMs 
To examine possible actions of cancer cells on the electrical characteristics of 
cardiomyocytes, the influence of cancer cell secretion on action potential (AP) 
of hiPSC-CMs were investigated (Figure 5). The results exhibited that the 
maximum depolarization velocity (Vmax) and the action potential amplitude (APA) 
were reduced in AGS and SW480 groups compared with control (without 




potential duration at 10% repolarization (APD 10) prolonged in the AGS and 
SW480 groups, while the action potential duration at 50% repolarization (APD 
50) and 90% repolarization (APD 90) and the resting potential (RP) were similar 
in all groups. In addition, the effects of cancer cell secretion on AP paced at 








Figure 5. Action potential (AP) characteristics of hiPSC-CMs cultured with AGS and 
SW480 cancer cell media. “Ctr” represents data from hiPSC-CMs without medium for 
cancer cells. “Medium” represents data from hiPSC-CMs with addition of un-cultured 
medium for cancer cells. “AGS” represents data from hiPSC-CMs with addition of cultured 
medium of AGS cancer cells. “SW480” represents data from hiPSC-CMs with addition of 
cultured medium of SW480 cancer cells. Data are presented as mean ± SEM and analyzed 
by one-way ANOVA. The cell number (n) of every experiment group is marketed on the 
column. *P<0.05, **P<0.01, ***P<0.001. 
 
5.3 Effects of cancer cell secretion on ion channel currents in hiPSC-CMs 
In order to uncover the ion channel current alterations responsible for the 
observed AP changes, voltage clamp recordings were performed. Different ion 
channel currents that contribute to APs were investigated. Specifically, the peak 
and late Na+ current (INa), the L-type Ca2+ current (ICa-L), the Na+/Ca2+ 
exchanger current (INCX) and K+ channel currents including the transient 
outward (Ito), the rapidly activating delayed rectifier (IKr), the slowly activating 
delayed rectifier (IKs) and the inward rectifier (IK1) were assessed. The peak INa 
was significantly reduced in AGS and SW480 groups compared with control 




Vmax and APA of APs. The activation, inactivation and recovery curves of INa 
were not significantly changed (Figure 6C, D, E, F, G, H). The late sodium 
current increased in AGS and SW480 groups when compared with control and 
medium groups (Figure 6J).  
 
Figure 6. The sodium current was suppressed in hiPSC-CMs cultured with AGS and 
SW480 cancer cell media. (A) I-V curves of peak INa. (B) Mean values of peak INa at -
40mV. (C) Activation curves of peak INa. (D) Mean values of V0.5 (the voltage at half 
maximum) of activation. (E) Inactivation curves of peak INa. (F) Mean values of V0.5 of 
inactivation. (G) Time course curves of recovery from inactivation of peak INa. (H) Mean 
values of time constants (tau) of recovery from inactivation (I) Representative traces of INa 




represents data from hiPSC-CMs without medium for cancer cells. “Medium” represents 
data from hiPSC-CMs with addition of un-cultured medium for cancer cells. “AGS” 
represents data from hiPSC-CMs with addition of cultured medium of AGS cancer cells. 
“SW480” represents data from hiPSC-CMs with addition of cultured medium of SW480 
cancer cells. Data are presented as mean ± SEM and analyzed by one-way ANOVA. The 
cell number of every experiment group is given as” n”. *P<0.05. 
 
The sodium-calcium exchanger current, INCX, was similar in all the 
experimental groups (Figure 7). Neither the I-V curves of L-type Ca2+ current 
nor the channel gating kinetics (activation, inactivation and recovery from 
inactivation) were changed by the cancer cell secretion (Figure 8).  
 
 
Figure 7. The sodium-calcium exchanger current (INCX) in hiPSC-CMs cultured with 
AGS and SW480 cancer cell media. (A) Mean values of INCX at 50mV and -85mV. (B) 
Representative traces of INCX in Ctrl, medium, AGS, and SW480 groups. “Ctr” represents 
data from hiPSC-CMs without medium for cancer cells. “Medium” represents data from 
hiPSC-CMs with addition of un-cultured medium for cancer cells. “AGS” represents data 
from hiPSC-CMs with addition of cultured medium of AGS cancer cells. “SW480” 
represents data from hiPSC-CMs with addition of cultured medium of SW480 cancer cells. 
Data are presented as mean ± SEM and analyzed by one-way ANOVA. The cell number 





Figure 8. The L-type calcium current (ICa-L) in hiPSC-CMs cultured with AGS and 
SW480 cancer cell media. (A) I-V curves of ICa-L. (B) Mean values of peak ICa-L at -10mV. 
(C) Activation curves of ICa-L. (D) Mean values of V0.5 (the voltage at half maximum) of 
activation. (E) Inactivation curves of peak ICa-L. (F) Mean values of V0.5 of inactivation. (G) 
Time course curves of recovery from inactivation of ICa-L. (H) Mean values of time constants 
(tau) of recovery from inactivation. (I) Representative traces of ICa-L in Ctrl, medium, AGS, 
and SW480 groups. “Ctr” represents data from hiPSC-CMs without medium for cancer 
cells. “Medium” represents data from hiPSC-CMs with addition of un-cultured medium for 




AGS cancer cells. “SW480” represents data from hiPSC-CMs with addition of cultured 
medium of SW480 cancer cells. Data are presented as mean ± SEM and analyzed by one-
way ANOVA. The cell number of every experiment group is shown as” n”. 
 
The K+ channel currents were differentially affected by the cancer cell 
secretion. Ito, the 4-AP (an Ito blocker) sensitive current, was declined in AGS 
and SW480 groups compared with control and medium groups (Figure 9), 
consistent with the prolongation of APD10.  
 
Figure 9. The transient outward current (Ito) decreased in hiPSC-CMs cultured with 
AGS and SW480 cancer cell media. (A) I-V curves of Ito. (B) Mean values of peak Ito at 
60mV. (C) Representative traces of Ito in Ctrl, medium, AGS, and SW480 groups. “Ctr” 
represents data from hiPSC-CMs without medium for cancer cells. “Medium” represents 
data from hiPSC-CMs with addition of un-cultured medium for cancer cells. “AGS” 
represents data from hiPSC-CMs with addition of cultured medium of AGS cancer cells. 
“SW480” represents data from hiPSC-CMs with addition of cultured medium of SW480 
cancer cells. Data are presented as mean ± SEM and analyzed by one-way ANOVA. “n” 
represents the cell number of every group. *P<0.05, **P<0.01. 
 
The rapidly activating delayed rectifier potassium current (IKr) slightly 
increased (Figure 10), while the slowly activating delayed rectifier K+ current, 
(IKs), was significantly higher in the cancer groups compared with control and 
medium groups (Figure11). The inward rectifier potassium current (IK1) 





Figure 10. The rapidly activating delayed rectifier potassium current (IKr) in hiPSC-
CMs cultured with AGS and SW480 cancer cell media. (A) I-V curves of IKr. (B) Mean 
values of IKr at 30mV. (C) Representative traces of IKr in Ctrl, medium, AGS, and SW480 
groups. “Ctr” represents data from hiPSC-CMs without medium for cancer cells. “Medium” 
represents data from hiPSC-CMs with addition of un-cultured medium for cancer cells. 
“AGS” represents data from hiPSC-CMs with addition of cultured medium of AGS cancer 
cells. “SW480” represents data from hiPSC-CMs with addition of cultured medium of 
SW480 cancer cells. Data are presented as mean ± SEM and analyzed by one-way 
ANOVA. The cell number of every experiment group is marketed as” n”. 
 
 
Figure 11. The slowly activating delayed rectifier K+ current (IKs) in hiPSC-CMs 
cultured with AGS and SW480 cancer cell media. (A) I-V curves of IKs. (B) Mean values 
of peak IKs at 40mV. (C) Representative traces of IKs in Ctrl, medium, AGS, and SW480 
groups. “Ctr” represents data from hiPSC-CMs without medium for cancer cells. “Medium” 
represents data from hiPSC-CMs with addition of un-cultured medium for cancer cells. 
“AGS” represents data from hiPSC-CMs with addition of cultured medium of AGS cancer 
cells. “SW480” represents data from hiPSC-CMs with addition of cultured medium of 
SW480 cancer cells. Data are presented as mean ± SEM and analyzed by one-way 





Figure 12. The inward rectifier potassium current (IK1) in hiPSC-CMs cultured with 
AGS and SW480 cancer cell media. (A) I-V curves of IK1. (B) Mean values of IK1 at -
120mV. (C) Representative traces of IK1 in Ctrl, medium, AGS, and SW480 groups. “Ctr” 
represents data from hiPSC-CMs without medium for cancer cells. “Medium” represents 
data from hiPSC-CMs with addition of un-cultured medium for cancer cells. “AGS” 
represents data from hiPSC-CMs with addition of cultured medium of AGS cancer cells. 
“SW480” represents data from hiPSC-CMs with addition of cultured medium of SW480 
cancer cells. Data are presented as mean ± SEM and analyzed by one-way ANOVA. The 
cell number of every experiment group is marketed as” n”. 
 
5.4 Effects of cancer cell secretion on ion channel expression in hiPSC-
CMs 
To investigate whether cancer secretions affect the expression of ion channels, 
PCR-analysis was carried out to assess the ion channel expression profile at 
mRNA level in hiPSC-CMs. PCR results showed that the expression of SCN5A 
(Na+ channel, Nav1.5), KCND3 (Ito, Kv4.3) and KCNJ2 (Kir2.1, IK1) was decreased 
in hiPSC-CMs with cancer cell medium (the AGS and SW480 groups) when 
compared with that in hiPSC-CMs treated with un-cultured cancer cell medium 
(the control  group) (Figure 13). However, the level of SCN10A (Na+ channel, 




of CACNA1C (L-type Ca2+ channel), SLC8A1 (NCX, Na+-Ca2+ exchanger) 
showed no difference among AGS and SW480 and control groups.  
Since the culture media for cancer cells and cardiomyocytes were different, 
the possible effects of different concentrations of un-cultured cancer cell 
medium on channel expression were also examined at the same time. It 
showed that the cancer cell medium without cancer cell secretion had no 
influence on the expression of ion channels in cardiomyocytes (Figure 14).  
 
Figure 13. Ion channel expression profile at mRNA level in hiPSC-CMs cultured with 
different concentration of AGS and SW480 cancer cell media. Different concentration 
of cancer culture medium from flasks with cancer cells cultured for 8 days were added into 




levels of different ion channels. “Ctr” represents data from hiPSC-CMs without medium for 
cancer cells. “AGS” represents data from hiPSC-CMs with addition of cultured medium of 
AGS cancer cells. “SW480” represents data from hiPSC-CMs with addition of cultured 
medium of SW480 cancer cells. Data are presented as mean ± SEM and analyzed by one-
way ANOVA. The experimental (biological replicates) number of every experiment group 
is indicated as “n”. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. 
 
 
Figure 14. Ion channel expression profile at mRNA level in hiPSC-CMs cultured with 
different concentration of cancer culture medium without influence of cancer cells. 
Different concentration of cancer culture medium from flasks without cancer cells were 
added into flasks with hiPSC-CMs for 2 days. qPCR analysis was performed to evaluate 
expression levels of ion channels. “Ctr” represents data from hiPSC-CMs without medium 
for cancer cells. “Medium” represents data from hiPSC-CMs with addition of uncultured 
medium for cancer cells. Data are presents as mean ± SEM and analyzed by one-way 
ANOVA. The experimental (biological replicates) number of every experiment group is 
indicated as “n”. 
 
Then we checked the protein expression levels of channels. The western 
blotting analysis showed that SCN5A was decreased, whereas SCN10A was 
increased; CACNA1C and Na+/ Ca2+ exchanger NCX were not changed (Figure 




unchanged (Figure 16). All the results were in accordance with PCR assays 
and current measurements. 
 
Figure 15. Protein expression levels of SCN5A, SCN10A, CACNA1C and NCX in 
hiPSC-CMs cultured with AGS and SW480 cancer cell media. (A) Protein bands 
detected with SCN5A antibody. (B) Statistical analyses of relative expression level of 
SCN5A. (C) Protein bands detected with SCN10A antibody. (D) Statistical analyses of 
relative expression level of SCN10A. (E) Protein bands detected with CACNA1C antibody. 
(F) Statistical analyses of relative expression level of CACNA1C.(G)Protein bands 




“Ctr” represents data from hiPSC-CMs without medium for cancer cells. “Medium” 
represents data from hiPSC-CMs with addition of un-cultured medium for cancer cells. 
“AGS” represents data from hiPSC-CMs with addition of cultured medium of AGS cancer 
cells. “SW480” represents data from hiPSC-CMs with addition of cultured medium of 
SW480 cancer cells. Data are presented as mean ± SEM and analyzed by one-way 







Figure 16. Protein expression levels of KCND3, KCNQ1, HERG and KCNJ2 in hiPSC-
CMs cultured with AGS and SW480 cancer cell media. (A) Protein bands detected with 
KCND3 antibody. (B) Statistical analyses of relative expression level of KCND3. (C) Protein 
bands detected with KCNQ1 antibody. (D) Statistical analyses of relative expression level 
of KCNQ1. (E) Protein bands detected with HERG antibody. (F) Statistical analyses of 
relative expression level of HERG. (G) Protein bands detected with KCNJ2 antibody. (H) 
Statistical analyses of relative expression level of KCNJ2. “Ctr” represents data from 
hiPSC-CMs without medium for cancer cells. “Medium” represents data from hiPSC-CMs 
with addition of un-cultured medium for cancer cells. “AGS” represents data from hiPSC-
CMs with addition of cultured medium of AGS cancer cells. “SW480” represents data from 
hiPSC-CMs with addition of cultured medium of SW480 cancer cells. Data are presented 
as mean ± SEM and analyzed by one-way ANOVA. The experimental number of every 
experiment group is marketed as “n”. *P<0.05, **P<0.01. 
 
To further assess changes of channel proteins in sarcolemma membrane, 
the immunofluorescence technique was applied to assess the expression of ion 
channels on the membrane, focusing on the transient outward K+ channel , the 
slowly activating delayed rectifier K+ channel and the Na+ channel. As shown 
in Figure 17, the expression levels of SCN5A and KCND3 in cell membrane 






Figure 17. Immunofluorescence analysis of Na+ and K+ channels in human induced 
pluripotent stem cell–derived cardiomyocytes (hiPSC-CM). (A) Immunofluorescence 
detecting the expression of α-actinin (red) and KCND3 (green). (B) Statistical analyses of 




α-actinin (red) and KCNQ1 (green). (D) Statistical analyses of relative expression level of 
KCNQ1. (E) Immunofluorescence detecting the expression with α-actinin (red) and SCN5A 
(green). (F) Statistical analyses of relative expression level of SCN5A. “Ctr” represents 
data from hiPSC-CMs without medium for cancer cells. “Medium” represents data from 
hiPSC-CMs with addition of un-cultured medium for cancer cells. “AGS” represents data 
from hiPSC-CMs with addition of cultured medium of AGS cancer cells. “SW480” 
represents data from hiPSC-CMs with addition of cultured medium of SW480 cancer cells. 
Scale bars, 20μm. Data are presented as mean ± SEM and analyzed by one-way ANOVA. 
The cell number of every experiment group is marketed as” n”. *P<0.05, **P<0.01, 
***P<0.001. 
 
5.5 Cancer cell secretion enhanced the DNA methylation of genome and 
ion channel genes  
To examine the potential epigenetic mechanism by which GI cancers cause ion 
channel dysfunctions and action potential prolongation, the levels of whole 
genome DNA methylation and DNA demethylation were both measured. The 
dot blotting results showed that the level of 5-methylcytosine (5-mC, indicating 
DNA methylation) but not 5-hydroxymethylcytosine (5-hmC, indicating DNA 
demethylation) was higher in AGS and SW480 groups compared with the 
control and medium groups (Figure 18). These data indicated that epigenetic 
modification of DNA methylation was enhanced in the cardiomyocytes treated 





Figure 18. The level of whole genome DNA methylation in hiPSC-CMs cultured with 
AGS and SW480 cancer cell media. (A) 5-mC levels detected by dot blotting. (B) 5hmC 
levels detected by dot blotting. “Ctr” represents data from hiPSC-CMs without medium for 
cancer cells. “Medium” represents data from hiPSC-CMs with addition of un-cultured 
medium for cancer cells. “AGS” represents data from hiPSC-CMs with addition of cultured 
medium of AGS cancer cells. “SW480” represents data from hiPSC-CMs with addition of 
cultured medium of SW480 cancer cells. 
 
To further investigate whether cancer secretion changes the DNA 
methylation in specific ion channel genes, we evaluated the methylation levels 
of CpG islands of promoters of Ito (KCND3), IKs (KCNQ1) and INa (SCN5A) 
channel genes (Figure 19). The methylation levels of CpG islands of KCND3 
were higher in cancer secretion groups, while the methylation levels of KCNQ1 
were lower than those in control and medium groups. No difference of 







Figure 19. The methylation level of CpG islands of promoters. (A) The methylation 
level of CpG islands of promoters of KCND3. (B) The methylation level of CpG islands of 
promoters of KCNQ1. (C) The methylation level of CpG islands of promoters of SCN5A. 
“Ctr” represents data from hiPSC-CMs without medium for cancer cells. “Medium” 
represents data from hiPSC-CMs with addition of un-cultured medium for cancer cells. 
“AGS” represents data from hiPSC-CMs with addition of cultured medium of AGS cancer 
cells. “SW480” represents data from hiPSC-CMs with addition of cultured medium of 
SW480 cancer cells. The circles show different methylation sites. Different dark color in 
circles represents different percentage of methylation. 
 
5.6 The expression of DNA methylation enzymes was elevated by cancer 
cell secretion 
DNMTs are the main enzymes responsible for DNA methylation. We further 
checked the protein levels of DNMT1 (Figure 20 A, B), DNMT2 (Figure 20 C, 
D), DNMT3A (Figure 20 E, F) and DNMT3B (Figure 20 G, H). We found that 
DNMT3A and 3B levels were increased significantly in cancer cell secretion 
groups, in agreement with the elevated methylation in DNA. The TET enzyme 
family is responsible for DNA demethylation. Next, TET1 antibody was selected 
to detect the protein level of DNA demethylation enzymes. The level of TET1 





Figure 20. Protein expression levels of DNMTs and TET1 enzymes in hiPSC-CMs 
cultured with AGS and SW480 cancer cell media. (A) Protein bands detected with 




bands detected with DNMT2 antibody. (D) Statistical analyses of relative expression level 
of DNMT2. (E) Protein bands detected with DNMT3A antibody. (F) Statistical analyses of 
relative expression level of DNMT3A. (G) Protein bands detected with DNMT3B antibody. 
(H) Statistical analyses of relative expression level of DNMT3B. (I) Protein bands detected 
with TET1antibody. (J) Statistical analyses of relative expression level of TET1. “Ctr” 
represents data from hiPSC-CMs without medium for cancer cells. “Medium” represents 
data from hiPSC-CMs with addition of un-cultured medium for cancer cells. “AGS” 
represents data from hiPSC-CMs with addition of cultured medium of AGS cancer cells. 
“SW480” represents data from hiPSC-CMs with addition of cultured medium of SW480 
cancer cells. Data are presented as mean ± SEM and analyzed by one-way ANOVA. The 
number of every experiment group is marketed as “n”. *P<0.05, **P<0.01. 
 
5.7 Overexpression of TET1 attenuated the enhancement of DNA 
methylation by cancer cell secretion 
To prove that the observed changes of ion channel expression induced by 
cancer cell secretion are related to the enhanced DNA methylation, we 
intended to reduce the methylation by overexpression of TET1. For selecting a 
better concentration of plasmid DNA for transfection, different amounts of 
plasmid FH-TET1-pEF were tested, western blotting and dot blotting were 
adopted to detect the expression levels. The protein level of TET1 (Figure 21) 
was similar when 0.4µg and 1µg plasmid were applied, but the 5-
hydroxymethylcytosine level (5-hmc) (Figure 22) was higher when the added 





Figure 21. Protein expression levels of TET1 enzymes in hiPSC-CMs transfected 
with different amount of TET1 plasmid. (A) Protein bands detected with TET1 antibody. 
(B) Statistical analyses of relative expression level of TET1. “Ctr” represents data from 
hiPSC-CMs without transfection. “Empty” represents data from hiPSC-CMs transfected 
with empty plasmid. “TET1-0.4µg” represents data from hiPSC-CMs transfected with 0.4µg 
TET1 plasmid DNA. “TET1-1µg” represents data from hiPSC-CMs transfected with 1µg 
TET1 plasmid DNA. Data are presented as mean ± SEM and analyzed by one-way ANOVA. 
The experimental number of every experiment group is marketed as “n”. *P<0.05. 
 
 
Figure 22. The level of whole genome DNA methylation after overexpression of TET1. 
(A) 5-mC levels detected by dot blotting. (B) 5-hmC levels detected by dot blotting. “Ctr” 
represents data from hiPSC-CMs without transfection. “Empty” represents data from 
hiPSC-CMs transfected with empty plasmid. “TET1-0.4µg” represents data from hiPSC-
CMs transfected with 0.4µg TET1 plasmid DNA. “TET1-1μg” represents data from hiPSC-
CMs transfected with 1μg TET1 plasmid DNA. 
 
After transfection, the TET1 plasmid but not the empty plasmid increased the 
protein level of TET1 in hiPSC-CMs, independent of cancer secretions (Figure 
23). Under this condition, the levels of 5-methylcytosine (5-mc) and the 5-
hydroxymethylcytosine (5-hmc) were again measured by dot blotting. The 




after overexpression of TET1 in hiPSC-CMs treated with cancer secretions 
(figure 24). 
 
Figure 23. Protein expression levels of TET1 enzymes in hiPSC-CMs after 
overexpression of TET1. HiPSC-CMs were transfected with 1μg TET1 plasmid DNA or 
the empty plasmid. The protein level of TET1 was analyzed by western blotting. (A) Protein 
bands detected with TET1antibody. (B) Statistical analyses of relative expression level of 
TET1. “Ctr” represents data from hiPSC-CMs without transfection. “Empty” represents data 
from hiPSC-CMs transfected with empty plasmid. “TET1” represents data from hiPSC-CMs 
transfected with 1μg TET1 plasmid DNA. “AGS” represents data from hiPSC-CMs with 
addition of cultured medium of AGS cancer cells without transfection. “A+T” represents 
data from hiPSC-CMs with addition of cultured medium of AGS cancer cells and 
transfected with 1μg TET1 plasmid DNA. “SW480” represents data from hiPSC-CMs with 
addition of cultured medium of SW480 cancer cells without transfection. “S+T” represents 
data from hiPSC-CMs with addition of cultured medium of SW480 cancer cells and 
transfected with 1μg TET1 plasmid DNA. Data are presented as mean ± SEM and 






Figure 24. The level of whole genome DNA methylation in hiPSC-CMs treated with cancer 
cell secretion was attenuated after overexpression of TET1. HiPSC-CMs were transfected 
with 1ug TET1 plasmid DNA or the empty plasmid. The DNA methylation level of was analyzed 
by dot blotting. (A) 5-mC levels detected by dot blotting. (B) 5-hmC levels detected by dot 
blotting. “Ctr” represents data from hiPSC-CMs without transfection. “AGS” represents data 
from hiPSC-CMs with addition of cultured medium of AGS cancer cells, but without transfection. 
“A+T” represents data from hiPSC-CMs with addition of cultured medium of AGS cancer cells 
and transfected with 1μg TET1DNA. “SW480” represents data from hiPSC-CMs with addition 
of cultured medium of SW480 cancer cells but without transfection. “S+T” represents data from 
hiPSC-CMs with addition of cultured medium of SW480 cancer cells and transfected with 1μg 
TET1 DNA. 
 
5.8 Reduction of DNA methylation reversed the effects of cancer cell 
secretion on expression levels of ion channels  
To assess whether the changes in DNA methylation level induced by cancer 
cell secretion are responsible for ion channel dysfunctions, the protein 
expression levels of KCND3, KCNQ1, SCN5A, SCN10A were evaluated in cells 
transfected with TET1 reducing the DNA methylation level. The western blotting 
analysis displayed that the transient outward current (KCND3) and the slowly 
activating delayed rectifier K+ channel (KCNQ1) were rescued after 
overexpression of TET1, while the Na+ channels (SCN5A and SCN10A) 





Figure 25. Protein expression levels of KCND3, KCNQ1, SCN5A, SCN10A in hiPSC-
CMs after overexpression of TET1. HiPSC-CMs were transfected with 1μg TET1 plasmid 
DNA or the empty plasmid. The protein level of ion channels was analyzed by western 
blotting. (A) Protein bands detected with KCND3 antibody. (B) Statistical analyses of 
relative expression level of KCND3. (C) Protein bands detected with KCNQ1 antibody. (D) 
Statistical analyses of relative expression level of KCNQ1. (E) Protein bands detected with 
SCN5A antibody. (F) Statistical analyses of relative expression level of SCN5A. (G) Protein 
bands detected with SCN10A antibody. (H) Statistical analyses of relative expression level 




“AGS” represents data from hiPSC-CMs with addition of cultured medium of AGS cancer 
cells. “A+T” represents data from hiPSC-CMs with addition of cultured medium of AGS 
cancer cells and transfected with 1μg TET1 plasmid DNA. “SW480” represents data from 
hiPSC-CMs with addition of cultured medium of SW480 cancer cells. “S+T” represents 
data from hiPSC-CMs with addition of cultured medium of SW480 cancer cells and 
transfected with 1μg TET1 plasmid DNA. Data are presented as mean ± SEM and 
analyzed by one-way ANOVA. The experimental number of every experiment group is 
marketed as “n”. *P<0.05. 
 
5.9 Overexpression of TET1 changed ion channel currents 
Finally, we examined the influences of DNA methylation level on ion channel 
functions. When TET1 was overexpressed (DNA methylation level was reduced) 
in hiPSC-CMs treated with cancer cell secretion, the transient outward current 
(Ito) currents were rescued to an extent similar to the control group (Figure 26). 
Similarly, the slowly activating delayed rectifier K+ current (IKs) was also 
corrected after overexpression of TET1 (Figure 27). However, the peak INa and 
late INa were not changed by the overexpression of TET1 (Figure 28). 
 
Figure 26. The transient outward current (Ito) of hiPSC-CMs after overexpression of 
TET1. HiPSC-CMs were transfected with 1μg TET1 plasmid DNA or the empty plasmid. 
The Ito channel currents were analyzed by patch clamp measurements.  (A) I-V curves of 
Ito. (B) Mean values of peak Ito at 60mV. (C) Representative traces of Ito in Ctrl, AGS, 
AGS+TET1, SW480 and SW480+TET1groups. Ctr” represents data from hiPSC-CMs 




addition of cultured medium of AGS cancer cells. “A+T” represents data from hiPSC-CMs 
with addition of cultured medium of AGS cancer cells and transfected with 1μg TET1 
plasmid DNA. “SW480” represents data from hiPSC-CMs with addition of cultured medium 
of SW480 cancer cells. “S+T” represents data from hiPSC-CMs with addition of cultured 
medium of SW480 cancer cells and transfected with 1μg TET1 plasmid DNA. Data are 
presented as mean ± SEM and analyzed by one-way ANOVA. The cell number of every 
experiment group is marketed as “n”.  *P<0.05. 
 
 
Figure 27. The slowly activating delayed rectifier K+ current (Iks) of hiPSC-CMs after 
overexpression of TET1. HiPSC-CMs were transfected with 1μg TET1 plasmid DNA or 
the empty plasmid. IKs was analyzed by patch clamp measurements. (A) I-V curves of IKs. 
(B) Mean values of peak IKs at 40mV. (C) Representative traces of Iks in Ctrl, AGS, 
AGS+TET, SW480 and SW480+TET groups. Ctr” represents data from hiPSC-CMs 
without transfection and cancer medium. “AGS” represents data from hiPSC-CMs with 
addition of cultured medium of AGS cancer cells. “A+T” represents data from hiPSC-CMs 
with addition of cultured medium of AGS cancer cells and transfected with 1μg TET1 
plasmid DNA. “SW480” represents data from hiPSC-CMs with addition of cultured medium 
of SW480 cancer cells. “S+T” represents data from hiPSC-CMs with addition of cultured 
medium of SW480 cancer cells and transfected with 1μg TET1 plasmid DNA. Data are 
presented as mean ± SEM and analyzed by one-way ANOVA. The cell number of every 





Figure 28. The sodium current of hiPSC-CMs after overexpression of TET1. HiPSC-
CMs were transfected with 1μg TET1 plasmid DNA or the empty plasmid. The peak Na+ 
currents were analyzed by patch clamp measurements.  (A) I-V curves of peak INa. (B) 
Mean values of peak INa at -40mV. (C) Activation curves of peak INa. (D) Mean values of 
V0.5 (the voltage at half maximum) of activation. (E) Inactivation curves of peak INa. (F) 
Mean values of V0.5 of inactivation. (G) Time course curves of recovery from inactivation 
of peak INa. (H) Mean values of time constants (tau) of recovery from inactivation. (H) Mean 
values of late INa at -40mV. (I) Representative traces of INa in Ctrl, AGS, AGS+TET1, 
SW480 and SW480+TET1 groups. Ctr” represents data from hiPSC-CMs without 




cultured medium of AGS cancer cells. “A+T” represents data from hiPSC-CMs with 
addition of cultured medium of AGS cancer cells and transfected with 1μg TET1 plasmid 
DNA. “SW480” represents data from hiPSC-CMs with addition of cultured medium of 
SW480 cancer cells. “S+T” represents data from hiPSC-CMs with addition of cultured 
medium of SW480 cancer cells and transfected with1μg TET1 plasmid DNA. Data are 
presented as mean ± SEM and analyzed by one-way ANOVA. The cell number of every 






In the present study, we investigated for the first time the effects of cancer cell 
secretion on ion channel functions and the underlying mechanism using hiPSC-
CMs. The novel findings of the study are: 1) the cancer cell secretion 
suppressed Vmax and APA of APs; 2) the cancer cell secretion prolonged APD; 
3) the cancer cell secretion down-regulated Na (Nav1.5) channels and up-
regulated Ito and IKs channels; 4) the cancer cell secretion up-regulated 
DNMT3A and DMNT3B, enhancing DNA methylation and leading to ion 
channel dysfunctions.  
To examine possible effects of cancer cell secretion (secreted components 
in culture medium) on APs and ion channel currents that contributed to the AP, 
we first measured the cell growth curve of the two cancer cell lines (AGS and 
SW40 cell lines) to determine the time point of media harvest. A typical growth 
curve for cultured cells is defined as 4 phases: (1) Lag phase. During this period, 
the cells adapt to the culture conditions. The length of this phase differs from 
different cell lines and is dependent on the seeding density. (2) Logarithmic 
growth phase. In this phase, cells proliferate actively, and the cell density arises 
exponentially. The cells are most viable at this period. (3) Plateau phase. The 
cell proliferation slows down at this phase and cells become confluent. (4) 
Decline phase. Cells die and viable cells decrease at this stage. After 
generation of the growth curve of AGS and SW480 cell lines by cell counting 
and MTT assay, we found that these two cancer cell lines reached plateau 
phase at day 8-9. So, we determined to harvest the cancer cell media at day 8 
in the end of the logarithmic growth phase with stable cancer cell number and 
secretion.  
Since the cancer cells and hiPSC-CMs were cultured in different media, we 
examined the potential effects of cancer cell media on the hiPSC-CM viability. 
The results showed that different concentrations (10%, 20%, 40%, 80%) of the 




indicating that the cancer cell secretion has no relevant effects on the growth 
of hiPSC-CMs. Then, we further examined the effects of different 
concentrations (10%, 20%, 40%, 80%) of cancer cell media without cancer cells 
(the medium control group) on the ion channel gene expression. The results 
showed that different concentrations of cancer cell media without cancer cells 
had no significant effects on the ion channel gene expression. This excluded 
the concern that the medium (for cancer cell culture) may influence hiPSC-CMs 
and also supported the interpretation of the results from hiPSC-CMs treated 
with cancer cell medium from the flask culturing cancer cells as effects of 
cancer cell secretion. In hiPSC-CMs treated by medium cultured with AGS and 
SW40 for 8 days, expressions of different ion channel genes including SCN5A, 
SCN10A, KCNQ1, KCND3 and KCNJ2 were changed, with an upregulation of 
SCN10A and KCNQ1, a downregulation of SCN5A and KCND3, which are 
indicative of influences of cancer cell secretion on ion channel regulation in 
cardiomyocytes. In high concentrations (40% and 80%) of cancer cell media, 
all these gene expressions seemed to be suppressed, indicating that high 
concentrations (40% and 80%) of cancer cell media might have detrimental 
effects on hiPSC-CMs. 20% of the cancer cell media from AGS and SW480 cell 
lines could cause significant changes of ion channel gene expression and had 
less effects on cell viability. Thus, we choose the concentration of 20% of the 
AGS and SW480 cancer cell media for the further experiments.  
Next, we measured APs paced at different frequencies and analyzed its 
characteristics in the hiPSC-CMs after 2-day treatment of AGS and SW480 
cancer cell media. We found that the Vmax of slope and the APA were decreased 
significantly, whereas the APD10 was prolonged at all frequencies (0.5Hz to 
3Hz). We further analyzed the ion channel currents that contributed to the AP 
and found that the peak INa was decreased significantly in the AGS and SW480 
group cardiomyocytes when compared with control and medium group. 




inactivation, and recovery from inactivation were not changed, suggesting that 
the reduction of peak INa resulted from reduced the channel proteins rather than 
gating changes. This is consistent with the PCR and western blot data showing 
reductions of both mRNA and protein level. The peak INa predominantly 
contributes to the phase 1 of AP. The decrease of Vmax and APA in 
cardiomyocytes treated with AGS and SW480 secretion can be explained by 
the decreased peak INa. The late INa was increased significantly by the AGS and 
SW480 secretion, which may prolong APD. The Ito current showed a significant 
decrease but the IKs current exhibited a significant increase in the AGS and 
SW480 group when compared with control and medium group. We also 
measured the ICa-L and IK1 but failed to detect any significant differences among 
these groups. The decrease in Ito may be the cause for the prolongation of 
APD10 since this phase is mainly determined by Ito. The increase in IKs should 
shorten APD, especially APD90. However, in the current study, APD50 and 
APD90 were not changed by AGS and SW40 cell secretion. This probably 
resulted from the counteraction of increased late INa and IKs, both of which can 
influence APD, but in opposite directions. ICa-L and IK1 as well as IKr are also 
important for determining APD. Given that these three currents were not 
significantly changed by cancer cell secretion, their contributions to the 
changes of APs are negligible. 
Since the mRNA and protein levels of the ion channels were changed after 
AGS and SW480 cancer cell media treatment, we further checked the whole 
genome DNA methylation level by dot blotting and the results showed that the 
5-mC but not 5-hmc level was increased significantly in AGS and SW480 group 
cardiomyocytes, indicating that the whole genome DNA methylation was 
increased after AGS and SW480 media treatment. The DNMTs are responsible 
for the establishment and maintenance of DNA methylation. We further 
checked the protein levels of DNMTs. The western blot showed that DNMT3a 




when compared with control and medium group, whereas DNMT1 and DNMT2 
seemed unchanged, indicating the hypermethylation in hiPSC-CMs treated with 
cancer cell secretion resulted from the upregulation of DNMT3a and DNMT3b. 
DNMTs dysregulation has been reported in gastrointestinal cancers.66 A 
measurement of DNMTs levels in different cancer cell lines and tissues showed 
that the mRNA levels of DNMT3a and 3b were significantly higher in colorectal 
cancers, and the protein level of DNMT1 was increased in colon tumors from 
patients compared to non-malignant mucosa from the same patients.67 In 
cancer cells, overexpressed DNMTs may be linked to the hypermethylation of 
tumor-suppressor genes.66 Many factors such as hypoxia or hypoglycemia may 
contribute to the dysregulation of DNMTs in colorectal cancer cells.68 In our 
study, the cancer cell secretion changed the DNMT3a and 3b levels in the 
hiPSC-CMs and further affected the DNA methylation in CpG islands of the 
promotors of different ion channel genes. This suggested that DNMTs were 
important intracellular regulators for gene expression not only in cancer cells 
but also in cardiomyocytes. 
Bisulfite sequencing is a method to determine the pattern of methylation in 
specific DNA sequence by using bisulfite treatment of DNA before normal 
sequence. Bisulfite treatment converts the unmethylated cytosine residues in 
DNA sequence into uracil and leaves the 5-mC unaffected. After PCR reaction 
with the specific primers targeting the CpG island in promoter regions of specific 
genes, the DNA sequences are amplified, and the uracil residues are replaced 
by thymine according to the rules of base pairing. Then the DNA sequences 
are purified and inserted into cloning vector and amplified in Escherichia coli. 
Comparison of the sequences after Sanger sequence shows the methylation 
patterns in the CpG island in the promoter regions. In our study, after Sanger 
sequence, we found that the DNA methylation was increased in the CpG island 
in promoter region of KCND3 gene in the AGS and SW480 group 




consistent with the decreased expression of KCND3 and increased levels of 
DNMT3a and 3b in cardiomyocytes in AGS and SW480 media treated groups 
since DNA methylation usually mediates an inhibitory effect on gene expression. 
The DNA methylation in the CpG island in promoter region of KCNQ1 gene was 
decreased after AGS and SW480 media treatment, which is in line with the 
increased expression of KCNQ1. But the reason why the methylation of CpGs 
was decreased in KCNQ1 promoter region when the DNMT3a and 3b were 
upregulated needed to be clarified by further investigations. The DNA 
methylation level in the CpG island in promoter region of SCN5A gene was 
similar among these groups, indicating DNA methylation might not be the main 
regulation of SCN5A expression after cancer cell secretion treatment. 
Since iPSC-CMs are highly differentiated cells, commonly used DNA 
methylation inhibitor 5-Azacytidine or 5-aza-2'-deoxycytidine cannot be used to 
inhibit the DNA methylation after treatment of cancer cell media. We 
overexpressed the TET1 in hiPSC-CMs to confirm the epigenetic mechanism 
of ion channel changes. As described above, TET1 is one of the enzymes that 
are responsible for the demethylation of DNA by catalyzing the conversion of 
the modified DNA base 5-mC to 5-hmC. We evaluated the TET1 protein level 
in TET1-overexpressed hiPSC-CMs. The protein level of TET1 was increased 
in the TET1-overexpressed cardiomyocytes indicating the overexpression 
model was established successfully. Then, we treated these TET1-
overexpressed cardiomyocytes with AGS and SW480 cancer cell media and 
detected the whole genome DNA methylation by dot blotting. We found that the 
5-mC level was reduced but the 5-hmC level was elevated after TET1 
overexpression, indicative of a reduction of methylation and an enhancement 
of demethylation. Under this condition, we further analyzed the protein levels of 
KCND3, KCNQ1, SCN5A and SCN10A. Protein levels of KCND3 and KCNQ1 
were also rescued after TET1 overexpression. However, TET1 overexpression 




might be other mechanisms for the regulation of SCN5A and SCN10A gene 
expression. 
To date, it is still unclear how the expression of DNMTs is changed in cancer 
cells. Firstly, mutation of the DNMTs genes may happen in some cancer cells. 
Emerging evidences suggested that epigenetic disruptions caused by DNMTs 
mutations were associated with tumorigenesis. DNMT1 mutations in coding 
exons were found in colorectal cancers and might potentially cause a genome-
wide alteration of DNA methylation.69 Mutations in DNMT3a were highly 
recurrent in patients with acute myeloid leukemia and were associated with 
poor event-free and overall survival.70 DNMT3A was also frequently mutated in 
acute and chronic myelomonocytic leukemia, and was associated with 
aggressiveness and drug resistance as well.71, 72 Secondly, infection of viruses 
can also change the expression of DNMTs. For gastrointestinal cancer, it is 
well-accepted that infection of Helicobacter pylori or Epstein-Barr virus (EBV) 
is one of the carcinogenic risk factors. H. pylori is reported to change DNMTs 
levels and total enzymatic activity in gastric cancer cells through activation of 
nuclear factor-κB (NF-κB) pathway via interleukin-1β (IL-1β) stimulation which 
led to the up-regulation of inducible nitric oxide synthase (iNOS) and increase 
of NO production.73 Another study also reported that IL-1β might play a crucial 
role in H. pylori-induced gastric inflammation and DNA methylation.74 On the 
other hand, EBV can induce DNA methylation by up-regulation of DNMT1 or 
DNMT3b through EBV latent membrane protein 2A (LMP2A).75, 76 EBV is also 
reported to induce DNMT1 expression through LMP1 via c-Jun N-terminal 
kinase (JNK)/activator protein-1 (AP1) signaling.77 Taking together, either 
genetic or environmental factors may regulate DNMTs. In our present study, 
the cancer cell secretion from two different GI cancer cell lines changed the 
level of DNMTs and further caused changes of expressions of the ion channel 
genes in hiPSC-CMs. This connected caner with cardiac disorders. But the 




unclear. It is believed that cancer cells could interact with the host cells and 
regulate their gene expression.17 Cancer cells might contribute to the DNMTs 
dysregulation in cardiomyocytes by secretion of cytokines or extracellular 
vesicles. Firstly, GI cancer cells can secrete cytokines such as IL-1β, IL-6, IL-
8, IL-11, etc.78, 79 These cytokines especially IL-1β can activate NF-κB pathway 
and lead to changes in expression levels of DNMTs as described above.73, 74 
Secondly, the extracellular vesicles including exosomes containing mRNAs, 
microRNAs (miRNAs) and proteins may regulate the expression of DNMTs in 
cancer cell media treated cardiomyocytes. 
Our present study is the first study to elucidate the effect of cancer cell 
secretion on cardiac ion channels expression and function and its potential 
mechanism in the hiPSC-CMs (Figure 29). We found that cancer cell secretion 
from two GI cancer cell lines could change the expression of DNMTs, which 
could further lead to the expression changes of the ion channel genes and 
cause electrophysiological abnormalities. However, further investigations are 
needed to clarify which components of cancer secretion changed the levels of 
DNMTs. Many components such as inflammatory factors and exosomes can 
be possible candidate factors that contribute to the regulation of DNMTs in 
cardiomyocytes and are to be investigated in future. Our findings in this study 
indentified one potential mechanism for cancer-induced cardiophysiological 
changes. But there might be other mechanisms. On one hand, secretions from 
cancer cells including cytokines and exosomes that containing RNAs and 
proteins might also directly affect the expression or trafficking or gating of ion 
channels. On the other hand, the cancer cell could indirectly affect the ion 
channel gene expressions through other proteins or genes, which are needed 





Figure 29. Potential mechanisms of effects of cancer cell secretion on hiPSC-CMs. 
Cancer secretion from GI cancer cells, AGS and SW480, containing mediators of 
epigenetic modification regulates the level of DNMTs and changes DNA methylation in 
promoter regions of ion channel genes. Epigenetic changes further cause changes in 









In summary, our results showed that GI cancer cell secretion could change the 
electrophysiology of human cardiac cells, especially the peak Na+ channel, the 
transient outward K+ channel, the slowly activating delayed rectifier K+ channel. 
The mechanism behind the electrophysiological changes caused by GI 
cancer cell secretion was at least partially through epigenetic modifications of 
ion channel genes by upregulating DNMTs.  
The ion channel dysfunctions caused by cancer cell secretion may contribute 
to arrhythmogenesis in cancer patients. Investigating the regulatory signaling, 
especially the epigenetic modifications of ion channels, may provide 
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